PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
22096499-9	2011	The synthetic compounds mianserin and epinastine, like cis-(Z)-flupentixol and spiperone, were found to have significant antagonist activity on AmDOP2 receptors.	Spiperone	79-88	dopamine receptor 2	Apis mellifera	144-150
21649638-0	2011	Involvement of the first transmembrane segment of human alpha(2) -adrenoceptors in the subtype-selective binding of chlorpromazine, spiperone and spiroxatrine.	Spiperone	132-141	adrenoceptor alpha 2A	Homo sapiens	56-79
21649638-1	2011	BACKGROUND AND PURPOSE: Some large antagonist ligands (ARC239, chlorpromazine, prazosin, spiperone, spiroxatrine) bind to the human alpha(2A) -adrenoceptor with 10- to 100-fold lower affinity than to the alpha(2B)- and alpha(2C)-adrenoceptor subtypes.	Spiperone	89-98	adrenoceptor alpha 2A	Homo sapiens	132-155
21649638-6	2011	KEY RESULTS: The affinities of three antagonists (spiperone, spiroxatrine and chlorpromazine) were significantly improved by TM1 substitutions of the alpha(2A)-adrenoceptor, but reciprocal effects were not seen for chimaeric receptors based on alpha(2B)- and alpha(2C)-adrenoceptors.	Spiperone	50-59	adrenoceptor alpha 2A	Homo sapiens	150-172
20804495-3	2010	EXPERIMENTAL APPROACH: The affinities of these compounds for the D(2) dopamine receptor were evaluated in competition with [(3) H]spiperone and [(3) H]NPA.	Spiperone	130-139	dopamine receptor D2	Homo sapiens	65-87
21765932-4	2011	Our previous study has shown that spiperone, a known antipsychotic drug, activates CaCCs and stimulates Cl(-) secretion in polarized human non-CF and CF airway epithelial cell monolayers in vitro, and in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) knockout mice in vivo.	Spiperone	34-43	CF transmembrane conductance regulator	Homo sapiens	204-255
21765932-4	2011	Our previous study has shown that spiperone, a known antipsychotic drug, activates CaCCs and stimulates Cl(-) secretion in polarized human non-CF and CF airway epithelial cell monolayers in vitro, and in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) knockout mice in vivo.	Spiperone	34-43	CF transmembrane conductance regulator	Homo sapiens	257-261
21765932-5	2011	Spiperone activates CaCC not by acting in its well-known role as an antagonist of either 5-HT2 or D2 receptors, but through a protein tyrosine kinase-coupled phospholipase C-dependent pathway.	Spiperone	0-9	chloride channel accessory 1	Homo sapiens	20-24
21765932-6	2011	Moreover, spiperone independently activates CFTR through a novel mechanism.	Spiperone	10-19	CF transmembrane conductance regulator	Homo sapiens	44-48
21765932-7	2011	Herein, we performed a mass spectrometry analysis and identified the signaling molecule that mediates the spiperone effect in activating chloride secretion through CaCC and CFTR.	Spiperone	106-115	chloride channel accessory 1	Homo sapiens	164-168
21765932-7	2011	Herein, we performed a mass spectrometry analysis and identified the signaling molecule that mediates the spiperone effect in activating chloride secretion through CaCC and CFTR.	Spiperone	106-115	CF transmembrane conductance regulator	Homo sapiens	173-177
21765932-9	2011	The inhibition of PYK2 notably reduced the ability of spiperone to increase intracellular Ca(2+) and Cl(-) secretion.	Spiperone	54-63	protein tyrosine kinase 2 beta	Homo sapiens	18-22
21765932-10	2011	In conclusion, we have identified the tyrosine kinase, PYK2, as the modulator, which plays a crucial role in the activation of CaCC and CFTR by spiperone.	Spiperone	144-153	protein tyrosine kinase 2 beta	Homo sapiens	55-59
21765932-10	2011	In conclusion, we have identified the tyrosine kinase, PYK2, as the modulator, which plays a crucial role in the activation of CaCC and CFTR by spiperone.	Spiperone	144-153	chloride channel accessory 1	Homo sapiens	127-131
21765932-10	2011	In conclusion, we have identified the tyrosine kinase, PYK2, as the modulator, which plays a crucial role in the activation of CaCC and CFTR by spiperone.	Spiperone	144-153	CF transmembrane conductance regulator	Homo sapiens	136-140
18987251-8	2009	Spiperone activates CaCCs, which stimulates Cl(-) secretion in polarized human non-CF and CF airway epithelial cell monolayers in vitro and in CFTR-knockout mice in vivo.	Spiperone	0-9	CF transmembrane conductance regulator	Homo sapiens	143-147
20122961-0	2010	Concentration of receptor and ligand revisited in a modified receptor binding protocol for high-affinity radioligands: [3H]Spiperone binding to D2 and D3 dopamine receptors.	Spiperone	119-132	dopamine receptor D2	Homo sapiens	144-172
19948059-4	2009	We identified spiperone, a psychotropic drug, as a novel Wnt inhibitor, which specifically blocks canonical Wnt signaling prior to the activation of beta-catenin.	Spiperone	14-23	catenin beta 1	Homo sapiens	149-161
18786164-7	2008	Spiperone markedly decreased the production of tumor necrosis factor-alpha in BV-2 microglia cells.	Spiperone	0-9	tumor necrosis factor	Mus musculus	47-74
18786164-8	2008	Spiperone attenuated the expression of inducible nitric oxide synthase and proinflammatory cytokines such as interleukin-1beta and tumor necrosis factor-alpha at mRNA levels in BV-2 microglia cells.	Spiperone	0-9	interleukin 1 beta	Mus musculus	109-158
15530890-7	2004	Total and subregional analysis of the striatum and nucleus accumbens showed that D-2 receptor ([3H]spiperone) binding density was increased while D-1 receptor ([3H]SCH 23390) and D-3 receptor ([3H]7-OH-DPAT) binding density was not altered.	Spiperone	99-108	dopamine receptor D2	Mus musculus	81-93
18786164-9	2008	Spiperone inhibited nuclear translocation and DNA binding of the p65 subunit of nuclear factor kappa B (NF-kappaB), inhibitor of kappa B (IkappaB) degradation, and phosphorylation of p38 mitogen-activated protein kinase in the lipopolysaccharide-stimulated BV-2 microglia cells.	Spiperone	0-9	mitogen-activated protein kinase 14	Mus musculus	183-186
17965538-4	2007	Selective 5-HT2A antagonists (risperidone, spiperone, ketanserin, AMI-193, and MDL 11,939) dose-dependently attenuated the hyperenzymemia; and their potency order, excepting that of ketanserin which has considerable affinity at the 5-HT2C receptor as well, paralleled their reported pKi values at the 5-HT2A receptor.	Spiperone	43-52	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	10-16
16822496-7	2006	Noradrenaline-induced contractions were competitively blocked by the selective alpha(1A)-adrenoceptor antagonists WB 4101 (pA(2)=8.88), phentolamine (pA(2)=8.39) and by the alpha(1B)-adrenoceptor antagonist spiperone (pA(2)=8.57), indicating the presence of functional alpha(1A)- and alpha(1B)-adrenoceptors.	Spiperone	207-216	adrenoceptor alpha 1A	Rattus norvegicus	79-101
19145332-1	2008	Pyloric stenosis and pancreatitis were simulated before and after administration of serotonin and spiperone (5-HT2 receptor blocker).	Spiperone	98-107	5-hydroxytryptamine receptor 2A	Homo sapiens	109-123
17167032-7	2007	The inhibition of basal [35S]GTPgammaS binding induced by maximally effective concentrations of spiperone (10 microM) or methiothepin (1 microM) was antagonized by WAY100,635 in a concentration-dependent manner (pKb, 9.52 and 8.87, respectively), thus indicating that this inverse agonism was mediated by 5-HT1A receptors.	Spiperone	96-105	5-hydroxytryptamine receptor 1A	Rattus norvegicus	305-311
16414597-1	2004	Spiperone is a potent dopamine (DA) D2, serotonin (5-hydroxy tryptamine, 5-HT) 5-HT(1A) and 5-HT(2A) antagonist.	Spiperone	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	79-86
15305090-2	2004	In the present study, the effects of a D2R agonist, bromocriptine, and a D2R antagonist, spiperone, on brain activity were investigated using wild-type mice (WT) with intact D2Rs, and D2R-knockout mice (D2R-KO) lacking D2Rs by functional magnetic resonance imaging.	Spiperone	89-98	dopamine receptor D2	Mus musculus	73-76
15305090-2	2004	In the present study, the effects of a D2R agonist, bromocriptine, and a D2R antagonist, spiperone, on brain activity were investigated using wild-type mice (WT) with intact D2Rs, and D2R-knockout mice (D2R-KO) lacking D2Rs by functional magnetic resonance imaging.	Spiperone	89-98	dopamine receptor D2	Mus musculus	73-76
15305090-2	2004	In the present study, the effects of a D2R agonist, bromocriptine, and a D2R antagonist, spiperone, on brain activity were investigated using wild-type mice (WT) with intact D2Rs, and D2R-knockout mice (D2R-KO) lacking D2Rs by functional magnetic resonance imaging.	Spiperone	89-98	dopamine receptor D2	Mus musculus	73-76
12435803-4	2002	The D(2)DR antagonist spiperone blocked quinpirole-elicited PTP inhibition, and the D(1) receptor agonist 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine (SKF38393) did not inhibit PTP activity, indicating that PTP inhibition is a specific effect mediated by stimulation of D(2)DR. We further discovered that striatal mitogen-activated protein kinase phosphatase (MKP), a protein phosphatase that is responsible for ERK dephosphorylation, is inhibited in response to D(2)DR stimulation in 6-OHDA-lesioned rats.	Spiperone	22-31	protein tyrosine phosphatase, non-receptor type 1	Rattus norvegicus	60-63
14634588-9	2003	On the other hand, the antagonist potencies of spiperone, AH11110A and cyclazosin were in agreement with an interaction on alpha(1B)-adrenoceptor subtype.	Spiperone	47-56	adrenoceptor alpha 1B	Homo sapiens	123-145
12767400-1	2003	We investigated sigma(1) and dopamine D(2) receptor occupancy in mouse brain after a single injection of haloperidol, nemonapride, or spiperone using [(11)C]SA4503 and [(11)C]raclopride, respectively.	Spiperone	134-143	dopamine receptor D2	Mus musculus	29-51
11961140-1	2002	Fusion proteins between the human 5-hydroxytryptamine (5-HT)(1A) receptor and either wild type or certain pertussis toxin-resistant forms of G(o1)alpha and G(i1)alpha display constitutive GTPase activity that can be inhibited by the inverse agonist spiperone.	Spiperone	249-258	5-hydroxytryptamine receptor 1A	Homo sapiens	34-73
12052193-0	2002	Ketanserin and spiperone as templates for novel serotonin 5-HT(2A) antagonists.	Spiperone	15-24	5-hydroxytryptamine receptor 2A	Homo sapiens	58-65
12052193-5	2002	Replacement of the N(1)-phenyl ring of spiperone with a methyl group (KML-010; 48) resulted in a compound that binds at 5-HT(2A) receptors with slightly lower affinity than spiperone, but that lacked affinity (Ki >10,000 nM) for 5-HT(2C) and 5-HT(1A) receptors and binds with 400-fold reduced affinity at D2 receptors.	Spiperone	39-48	5-hydroxytryptamine receptor 2A	Homo sapiens	120-127
12052193-5	2002	Replacement of the N(1)-phenyl ring of spiperone with a methyl group (KML-010; 48) resulted in a compound that binds at 5-HT(2A) receptors with slightly lower affinity than spiperone, but that lacked affinity (Ki >10,000 nM) for 5-HT(2C) and 5-HT(1A) receptors and binds with 400-fold reduced affinity at D2 receptors.	Spiperone	39-48	5-hydroxytryptamine receptor 2C	Homo sapiens	232-239
12052193-5	2002	Replacement of the N(1)-phenyl ring of spiperone with a methyl group (KML-010; 48) resulted in a compound that binds at 5-HT(2A) receptors with slightly lower affinity than spiperone, but that lacked affinity (Ki >10,000 nM) for 5-HT(2C) and 5-HT(1A) receptors and binds with 400-fold reduced affinity at D2 receptors.	Spiperone	39-48	5-hydroxytryptamine receptor 1A	Homo sapiens	245-252
12503636-0	2002	Nad-299 antagonises 5-HT-stimulated and spiperone-inhibited [35S]GTPgammaS binding in cloned 5-HT1A receptors.	Spiperone	40-49	5-hydroxytryptamine receptor 1A	Homo sapiens	93-99
11787947-10	2001	Spiperone-displaceable [3H]quinpirole binding was decreased to 43% of wild-type control; however, the remaining [3H]quinpirole binding in MAO(A)-deficient animals was inhibited by Ro 41-1049 similar to wild-type.	Spiperone	0-9	monoamine oxidase A	Rattus norvegicus	138-141
11020478-2	2000	The 5-HT(2A) receptor was characterized by the binding of [3H]MDL 100,907 (R(+)-alpha-(2, 3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidine-methan ol) to cortical membranes and the 5-HT(2C) receptor by the binding of [3H]mesulergine in the presence of the selective 5-HT(2A) receptor ligand spiperone.	Spiperone	301-310	5-hydroxytryptamine receptor 2A	Oryctolagus cuniculus	4-21
11226678-3	2001	Binding of [3H]SCH 23390 and [3H]spiperone to, respectively, D1 and D2 dopamine receptors was increased in transgenic mice.	Spiperone	33-42	dopamine receptor D2	Mus musculus	61-89
11459121-4	2001	5-Methylurapidil (5-HT1A agonist) and BMY7378 (5-HT1A agonist) showed, respectively, alpha1a(alpha1A)- or alpha1d(alpha1D)-subtype selectivity in both binding and functional affinities, but spiperone (5-HT2A antagonist) showed alpha1b-selectivity only in binding affinity.	Spiperone	190-199	5-hydroxytryptamine receptor 1A	Rattus norvegicus	18-24
11459121-4	2001	5-Methylurapidil (5-HT1A agonist) and BMY7378 (5-HT1A agonist) showed, respectively, alpha1a(alpha1A)- or alpha1d(alpha1D)-subtype selectivity in both binding and functional affinities, but spiperone (5-HT2A antagonist) showed alpha1b-selectivity only in binding affinity.	Spiperone	190-199	5-hydroxytryptamine receptor 1A	Rattus norvegicus	47-53
11401421-5	2001	The difference between effects of D2 and D3 dopamine receptor preferring antagonists applied locally was observed only in the degree of dopamine release elevation [the maximal responses were about 160% for haloperidol and spiperone, 190% for clozapine and ( +)-UH232 and 400% for ( +)-AJ76, of basal].	Spiperone	222-231	dopamine receptor D2	Rattus norvegicus	34-61
11078195-3	2000	Screening of the products at 5-HT2 and D2 receptors revealed 5-HT2A antagonists with improved selectivity compared to spiperone and AMI-193.	Spiperone	118-127	5-hydroxytryptamine receptor 2A	Homo sapiens	61-67
10633476-4	1999	The present study examines the effects of microinjection of a 5-HT1A agonist (8-OH-DPAT) and a 5-HT1A antagonist (spiperone) into the dorsal raphe nucleus (DRN) on AEP recorded epidurally from the primary and secondary auditory cortex in behaving cats.	Spiperone	114-123	legumain	Homo sapiens	164-167
10882396-7	2000	[(3)H]-Spiperone labelled a single, lower affinity site in HEK293 cells expressing h5-HT(1A) receptors but did not bind to native tissue 5-HT(1A) receptors.	Spiperone	7-16	5-hydroxytryptamine receptor 1A	Homo sapiens	84-91
10496950-4	1999	Spiperone functioned as an inverse agonist in membranes expressing the 5-HT(1A) receptor wild-type G(i1)alpha fusion protein and in those expressing 5-HT(1A) receptor (Ile(351))G(i1)alpha but not the 5-HT(1A) receptor (Gly(351))G(i1)alpha fusion protein.	Spiperone	0-9	5-hydroxytryptamine receptor 1A	Homo sapiens	71-88
10496950-4	1999	Spiperone functioned as an inverse agonist in membranes expressing the 5-HT(1A) receptor wild-type G(i1)alpha fusion protein and in those expressing 5-HT(1A) receptor (Ile(351))G(i1)alpha but not the 5-HT(1A) receptor (Gly(351))G(i1)alpha fusion protein.	Spiperone	0-9	5-hydroxytryptamine receptor 1A	Homo sapiens	149-166
10496950-4	1999	Spiperone functioned as an inverse agonist in membranes expressing the 5-HT(1A) receptor wild-type G(i1)alpha fusion protein and in those expressing 5-HT(1A) receptor (Ile(351))G(i1)alpha but not the 5-HT(1A) receptor (Gly(351))G(i1)alpha fusion protein.	Spiperone	0-9	5-hydroxytryptamine receptor 1A	Homo sapiens	149-166
10496950-5	1999	The effect of spiperone at the 5-HT(1A) receptor wild-type G(i1)alpha construct but not the 5-HT(1A) receptor (Ile(351))G(i1)alpha construct was blocked by pertussis toxin treatment.	Spiperone	14-23	5-hydroxytryptamine receptor 1A	Homo sapiens	31-48
10211591-3	1999	The effect of either 5-HT or DOI is blocked by selective 5-HT2A receptor antagonists such as spiperone and ketanserin and more markedly by mixed 5-HT2 receptor antagonists, such as ritanserin, methysergide and mesulergine, with higher affinity at the 2C subtype.	Spiperone	93-102	5-hydroxytryptamine receptor 2A	Rattus norvegicus	57-63
10344593-4	1999	Spiperone, a 5-HT1A antagonist, completely inhibited the response to 8-OH-DPAT but had no effect on Na+/K+-ATPase activity in cerebellum where LSD, a 5-HT6 agonist, elicited a dose-dependent response similar to that of 5-HT.	Spiperone	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	13-19
10381597-7	1999	The serotonergic effect was mimicked by the 5-HT1A specific agonist 8-OH DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) and blocked by the 5-HT1A antagonist spiperone.	Spiperone	156-165	5-hydroxytryptamine receptor 1A	Rattus norvegicus	138-144
10435390-10	1999	CONCLUSION: The finding that 7-OH-DPAT markedly attenuated the effects of morphine and that these effects were reversed with spiperone suggests that activity at the D3, and possibly the D2, receptor can modulate mu agonist-induced antinociception.	Spiperone	125-134	solute carrier family 3 member 1	Rattus norvegicus	186-198
10435413-10	1999	These effects of adenosine agonists and antagonists were abolished by prior administration of bromocriptine, the dopamine D2 receptor agonist and spiperone, the dopamine D2 receptor antagonist, respectively.	Spiperone	146-155	dopamine receptor D2	Mus musculus	161-181
9836624-7	1998	As such, N1-alkyl analogues of spiperone may afford entry into a novel series of 5-HT2A-selective antagonists.	Spiperone	31-40	5-hydroxytryptamine receptor 2A	Rattus norvegicus	81-87
10452091-8	1999	Moreover, the Fos protein expression induced by l-THP and spiperone could be prevented by the pre-treatment of the D2 agonist quinpirole but not D1 agonist SKF38393.	Spiperone	58-67	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	14-17
9678651-7	1998	Furthermore, pretreatment with a low or a high dose of the 5-HT1A/2A/dopamine D2 antagonist spiperone (0.01 or 3 mg/kg, s.c.) dose dependently shifted the alnespirone dose-response curve effect of alnespirone to the right.	Spiperone	92-101	5-hydroxytryptamine receptor 1A	Rattus norvegicus	59-65
9843378-9	1998	Removal of all the putative SH3 binding domains in the third intracellular loop of the dopamine D4 receptor resulted in a receptor that could still bind spiperone and dopamine.	Spiperone	153-162	dopamine receptor D4	Homo sapiens	87-107
9951623-3	1998	When injected into HeLa and HS24 cells in vitro, the vector induced an abundant message for D2R, as demonstrated by Northern analysis, and produced a membrane-bound protein capable of binding a D2R ligand, [3H]spiperone.	Spiperone	210-219	dopamine receptor D2	Homo sapiens	194-197
9951623-4	1998	When injected into rat striatum in vivo, the vector produced a marked increase in D2R near the site of injection, as evidenced by increased [3H]spiperone binding as well as by another more specific ligand, [125I]iodosulpride.	Spiperone	144-153	dopamine receptor D2	Homo sapiens	82-85
9836624-0	1998	Spiperone: influence of spiro ring substituents on 5-HT2A serotonin receptor binding.	Spiperone	0-9	5-hydroxytryptamine receptor 2A	Rattus norvegicus	51-57
9836624-1	1998	Spiperone (1) is a widely used pharmacological tool that acts as a potent dopamine D2, serotonin 5-HT1A, and serotonin 5-HT2A antagonist.	Spiperone	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	97-103
9836624-1	1998	Spiperone (1) is a widely used pharmacological tool that acts as a potent dopamine D2, serotonin 5-HT1A, and serotonin 5-HT2A antagonist.	Spiperone	0-9	5-hydroxytryptamine receptor 2A	Rattus norvegicus	119-125
9776346-17	1998	The L-NAME resistant component was antagonized by the 5-HT7 receptor antagonist spiperone (1 microM).	Spiperone	80-89	5-hydroxytryptamine receptor 7	Oryctolagus cuniculus	54-68
9774222-0	1998	Central administration of dopamine D3 receptor antisense to rat: effects on locomotion, dopamine release and [3H]spiperone binding.	Spiperone	109-122	dopamine receptor D3	Rattus norvegicus	26-46
9774222-1	1998	A 15-mer, all-phosphorothioate-modified antisense oligodeoxynucleotide (ASO) targeted against rat dopamine D3 receptor mRNA (4 microM, 5 days) significantly reduced (28%) the amount of binding sites labelled with [3H]spiperone in monolayer cultured Chinese hamster ovary (CHO) cells transfected with the complementary desoxyribonucleic acid (cDNA) for the rat D3 receptor.	Spiperone	217-226	dopamine receptor D3	Rattus norvegicus	98-118
9692774-9	1998	The I(TDS) was blocked by spiperone, a 5-HT1A receptor antagonist, in a concentration-dependent manner.	Spiperone	26-35	5-hydroxytryptamine receptor 1A	Rattus norvegicus	39-45
9687006-3	1998	In vas deferens from castrated rats, WB 4101 and spiperone showed slopes lower than 1.0 in the Schild plots, suggesting participation of multiple receptors.	Spiperone	49-58	arginine vasopressin	Rattus norvegicus	3-6
9707284-1	1998	The effects of three kinds of butyrophenones, haloperidol, droperidol and spiperone, on the N-methyl-D-aspartate (NMDA) receptor channel were examined on the epsilon1/zeta1, epsilon2/zeta1, epsilon3/zeta1 and epsilon4/zeta1 heteromeric NMDA receptor channels, expressed in Xenopus oocytes.	Spiperone	74-83	glutamate ionotropic receptor NMDA type subunit 1 L homeolog	Xenopus laevis	92-128
9698051-3	1998	LSD produced a dose-dependent inhibition of prolactin secretion in vitro with an IC50 at 1.7x10(-9) M. This action was antagonized by spiperone but not by SKF83566 or cyproheptadine, which indicates that LSD has a specific effect on D2 dopaminergic receptors.	Spiperone	134-143	prolactin	Rattus norvegicus	44-53
9730266-2	1998	The pharmacological profile and the anatomical localization of a putative dopamine D4 receptor were assessed in sections of rat and human atria and ventricles using combined radioligand binding and autoradiographic techniques with [3H]-spiperone as a ligand.	Spiperone	236-245	dopamine receptor D4	Rattus norvegicus	74-94
9730266-10	1998	[3H]-Spiperone binding was more sensitive to displacement by the neuroleptic clozapine in sections of atria than of ventricles, suggesting the expression of a dopamine D4 receptor in atrial tissue.	Spiperone	5-14	dopamine receptor D4	Homo sapiens	159-179
9730266-11	1998	Moreover, preincubation of some sections with a dopamine D4 receptor antibody and subsequent exposure to [3H]-spiperone caused a remarkable decrease of radioligand binding to sections of atria, but only a slight reduction of binding to sections of ventricles.	Spiperone	110-119	dopamine receptor D4	Homo sapiens	48-68
9535013-14	1998	Gamma-mangostin caused a concentration-dependent inhibition of the binding of [3H]-spiperone, a specific 5-HT2A receptor antagonist, to mouse brain membranes.	Spiperone	83-92	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	105-120
9415710-11	1997	The selective alpha 1A-AR antagonist WB-4101 and the alpha 1B-AR antagonist spiperone reduce PHE-induced pHi increases to a comparable extent.	Spiperone	76-85	calcium channel, voltage-dependent, N type, alpha 1B subunit	Mus musculus	53-61
9415710-11	1997	The selective alpha 1A-AR antagonist WB-4101 and the alpha 1B-AR antagonist spiperone reduce PHE-induced pHi increases to a comparable extent.	Spiperone	76-85	glucose-6-phosphate isomerase 1	Mus musculus	105-108
9443662-4	1997	The D1 and D2 dopamine receptor (DAR) specific binding of [3H]SCH 23390 and [3H]spiperone, respectively, during the 120 min period upon the treatment was examined on cryosections using computerized scanning and image analysis.	Spiperone	80-89	dopamine receptor D2	Rattus norvegicus	11-31
9326273-7	1997	In contrast to that in caudate, PLC activity in frontal cortex was stimulated by 5-HT in a manner that was inhibited by the 5-HT2A-selective antagonists, spiperone and ketanserin.	Spiperone	154-163	5-hydroxytryptamine receptor 2A	Rattus norvegicus	124-130
9402034-8	1997	Each of the [35S]GTP gamma S binding responses was mediated by a 5-HT1A receptor as indicated by the competitive blockade by WAY100635 and spiperone.	Spiperone	139-148	5-hydroxytryptamine receptor 1A	Homo sapiens	65-80
9313891-11	1997	Striatal D1 and D2 receptor-binding sites (measured with [3H]SCH23390 and [3H]spiperone binding, respectively) and mRNA levels for D1 and D2 receptors (determined with quantitative in situ hybridization) were altered after MPTP treatment in temporally independent manners.	Spiperone	78-87	deiodinase, iodothyronine, type I	Mus musculus	9-18
9178960-3	1997	The pharmacological profile of [3H]ketanserin binding was consistent with the labeling of the 5-HT2A receptor, since it revealed a competing drug potency ranking of ketanserin = spiperone > clozapine = haloperidol > methysergide > mesulergine > 5-HT.	Spiperone	178-187	5-hydroxytryptamine receptor 2A	Homo sapiens	94-109
9261814-4	1997	Desensitization of 5-HT1A receptors could be reversed by treatment of spiperone (1 mg kg-1, i.p.)	Spiperone	70-79	5-hydroxytryptamine receptor 1A	Rattus norvegicus	19-25
9212275-3	1997	The inhibitory effects of 5HT and the 5HT1A agonist 8-OH-DPAT were shown to be antagonized by the 5HT1A antagonists spiperone and pindolol, respectively, indicating involvement of a 5HT1A receptor.	Spiperone	116-125	5-hydroxytryptamine receptor 1A	Rattus norvegicus	38-43
9212275-3	1997	The inhibitory effects of 5HT and the 5HT1A agonist 8-OH-DPAT were shown to be antagonized by the 5HT1A antagonists spiperone and pindolol, respectively, indicating involvement of a 5HT1A receptor.	Spiperone	116-125	5-hydroxytryptamine receptor 1A	Rattus norvegicus	98-103
9212275-3	1997	The inhibitory effects of 5HT and the 5HT1A agonist 8-OH-DPAT were shown to be antagonized by the 5HT1A antagonists spiperone and pindolol, respectively, indicating involvement of a 5HT1A receptor.	Spiperone	116-125	5-hydroxytryptamine receptor 1A	Rattus norvegicus	98-103
9111066-6	1997	Pgp protein and pgp2/mdr1b mRNA was increased (maximum of 10- and 8-fold, respectively) by the potent D2 dopamine receptor agonists bromocriptine, R(-)-propylnorapomorphine hydrochloride, and quinpirole, and Pgp protein induction was blocked by D2 receptor antagonists spiperone and clozapine.	Spiperone	269-278	phosphoglycolate phosphatase	Rattus norvegicus	0-3
9111066-6	1997	Pgp protein and pgp2/mdr1b mRNA was increased (maximum of 10- and 8-fold, respectively) by the potent D2 dopamine receptor agonists bromocriptine, R(-)-propylnorapomorphine hydrochloride, and quinpirole, and Pgp protein induction was blocked by D2 receptor antagonists spiperone and clozapine.	Spiperone	269-278	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	21-26
9111066-6	1997	Pgp protein and pgp2/mdr1b mRNA was increased (maximum of 10- and 8-fold, respectively) by the potent D2 dopamine receptor agonists bromocriptine, R(-)-propylnorapomorphine hydrochloride, and quinpirole, and Pgp protein induction was blocked by D2 receptor antagonists spiperone and clozapine.	Spiperone	269-278	dopamine receptor D2	Rattus norvegicus	102-122
9111066-7	1997	D2 receptor agonist induction of pgp2/mdr1b mRNA was paralleled by transcriptional activation of the pgp2/mdr1b promoter but blocked by pretreatment with the D2 dopamine receptor antagonists, spiperone, eticlopride, and clozapine.	Spiperone	192-201	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	38-43
9111066-7	1997	D2 receptor agonist induction of pgp2/mdr1b mRNA was paralleled by transcriptional activation of the pgp2/mdr1b promoter but blocked by pretreatment with the D2 dopamine receptor antagonists, spiperone, eticlopride, and clozapine.	Spiperone	192-201	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	106-111
9176059-6	1997	The antagonists ketanserin, methysergide and spiperone attenuated the action of serotonin, while yohimbine and spiroxatrine were ineffectual, thus indicating that the potentiating effect was through the 5-HT1A receptor.	Spiperone	45-54	5-hydroxytryptamine receptor 1A	Homo sapiens	203-209
9138675-0	1997	Inhibition of the constitutive activity of human 5-HT1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635.	Spiperone	90-99	5-hydroxytryptamine receptor 1A	Homo sapiens	49-55
9138675-2	1997	In contrast, spiperone inhibited basal [35S]-GTP gamma S binding by 30.2% (IC50 = 55.5 nM) in CHO-5-HT1A membranes but not in control untransfected membranes.	Spiperone	13-22	5-hydroxytryptamine receptor 1A	Homo sapiens	98-104
9016944-6	1996	Indeed, both GR127935 and the 5-HT1A antagonist spiperone shift the EC50 for the residual effect of 5-HT from approximately 300 to 120-150 nM, suggesting that blocking one receptor subtype may facilitate activation of the other.	Spiperone	48-57	5-hydroxytryptamine receptor 1A	Homo sapiens	30-36
9203078-3	1997	The 5-HT1A/5-HT2 antagonist, spiperone, alone, had no effect on basal 5-HT synthesis, however it attenuated the effect of 8-OH-DPAT by 56% and CGS 12066B by 39% but only barely that of citalopram by 17%.	Spiperone	29-38	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
8967990-5	1996	The maximum number of binding sites (Bmax) estimated using [125I]L-750,667 in hD4 HEK cells was 251 +/- 71 fmol/mg, which correlated well with the Bmax value determined using [3H]spiperone (227 +/- 83 fmol/mg) in the same membrane preparations.	Spiperone	179-188	Rho GDP dissociation inhibitor beta	Homo sapiens	78-81
8853371-5	1996	The stimulatory effect of dopamine on the expression of pOGH (angiotensinogen N-1498/+18) was inhibited by the presence of SCH-23390 (D1-dopaminergic receptor antagonist) and spiperone (D2-dopaminergic receptor antagonist), but not by ketanserin (5 HT2/5HT1c-serotonergic receptor antagonist).	Spiperone	175-184	angiotensinogen	Homo sapiens	62-77
8886859-2	1996	Because haloperidol and spiperone are best known for actions at D2, 5HT2, alpha 1 and sigma (sigma) receptors, a series of agonists and antagonists of these receptors were tested.	Spiperone	24-33	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	68-72
8522980-1	1996	Three serine residues (Ser193, Ser194, Ser197) in the fifth transmembrane-spanning region of the D2 dopamine receptor have been mutated separately to alanine and the effects of the mutations determined in ligand-binding experiments with [3H] spiperone.	Spiperone	242-251	dopamine receptor D2	Rattus norvegicus	97-117
8684602-7	1996	The pain response produced by alpha-methyl-5-HT plus PGE2 was blocked by pretreatment with the 5-HT2A/2C antagonists ketanserin and ritanserin, and the 5-HT2A antagonist spiperone (MPE50 values 1.4, 7.7 and 0.06 nmol, respectively).	Spiperone	170-179	5-hydroxytryptamine receptor 2A	Rattus norvegicus	152-158
8979820-6	1996	In recordings of superficial layer neurons from SC slices, application of 5-HT during blockade of 5-HT1A receptors with spiperone reduced the amplitude of EPSPs evoked by stimulation of the optic tract.	Spiperone	120-129	5-hydroxytryptamine receptor 1A	Homo sapiens	98-104
8566173-4	1995	The 5-HT1A receptor antagonists spiperone and SDZ 216-525 completely abolished the effect of 8-OH-DPAT (IC50 30 nM for both drugs) behaving as pure antagonists.	Spiperone	32-41	5-hydroxytryptamine receptor 1A	Homo sapiens	4-19
8808147-6	1996	The 7-OH-DPAT- and quinpirole-induced decreases in serum prolactin levels were antagonized by the administration of the DA D2 receptor antagonist, spiperone, at 0.5 mg/kg.	Spiperone	147-156	prolactin	Rattus norvegicus	57-66
8577395-2	1995	Further, this 8-OH-DPAT-induced inhibition of forskolin-stimulated activity was significantly attenuated after pre-exposure to 5-HT (10 microM) for 12 h. Spiperone (10 microM), a 5-HT1A and 5-HT2A antagonist, prevented 5-HT-induced desensitization of 5-HT1A receptor, but a selective 5-HT2A receptor antagonist, ketanserin, did not.	Spiperone	154-163	5-hydroxytryptamine receptor 1A	Rattus norvegicus	179-191
7671319-5	1995	Spiperone and NAN-190, antagonists to 5-HT1A receptor subtype, abolished the serotonin effects on calcium signaling, whereas an agonist to 5-HT1A receptor, 8OHDPAT, mimicked the serotonin-like action on the diminution of the intracellular calcium contents.	Spiperone	0-9	5-hydroxytryptamine receptor 1A	Homo sapiens	38-53
7498319-6	1995	In contrast the affinity of the 5-HT1 receptor antagonists spiperone and methiothepine was much lower than their previously published potency at 5-HT1A receptors.	Spiperone	59-68	5-hydroxytryptamine receptor 1A	Rattus norvegicus	145-151
7501649-4	1995	Previous intra-DPAG administration of the 5-HT1A receptor blocker NAN-190 (40 nmol) antagonized the antiaversive effect of 8-OH-DPAT (8 nmol), whereas pretreatment with the 5-HT2A receptor blocker spiperone (10 nmol) antagonized the effect of DOI (16 nmol).	Spiperone	197-206	5-hydroxytryptamine receptor 1A	Rattus norvegicus	42-48
8616515-4	1995	The suppressive effect of quinpirole on NAT activity was blocked by spiroperidol and clozapine (antagonists of the D2 family of DA receptors), and not affected by SCH 23390 (an antagonist of the D1 family).	Spiperone	68-80	arylamine N-acetyltransferase, liver isozyme	Gallus gallus	40-43
8529048-4	1995	Dopamine D2-like receptor sites, which probably belong to the dopamine D2 receptor subtype, were characterized using [3H]-spiroperidol as a ligand.	Spiperone	122-134	dopamine receptor D2	Homo sapiens	62-82
7583680-5	1995	[3H]-spiperone autoradiography performed one day after the termination of dopamine infusion into the striatum revealed a dramatic reduction of D2-dopamine receptor binding.	Spiperone	5-14	dopamine receptor D2	Rattus norvegicus	143-163
7675121-10	1995	In the majority of cells tested, the effect of paroxetine was reversed by the 5-HT1A receptor antagonists spiperone or (+)WAY100135, implicating the involvement of the 5-HT1A autoreceptor.	Spiperone	106-115	5-hydroxytryptamine receptor 1A	Rattus norvegicus	78-84
7552250-3	1995	Binding of [3H]Sch-23390 and [3H]spiperone to D1 and D2 dopamine receptors, respectively, and [3H]8-hydroxy-2-(di-n-propylamino)-tetralin ([3H]8OH-DPAT) to 5-HT1A receptors were measured in various brain regions using quantitative autoradiography.	Spiperone	33-42	dopamine receptor D2	Rattus norvegicus	46-74
7582481-15	1995	The ligand specificity of the human 5-HT2B receptor (5-HT > ritanserin > SB 204741 > spiperone) was distinct from that of the human 5-HT2A (ritanserin > spiperone > 5-HT > SB 204741) and 5-HT2C (ritanserin > 5-HT > spiperone = SB 204741) receptors.	Spiperone	94-103	5-hydroxytryptamine receptor 2B	Homo sapiens	36-51
7582481-15	1995	The ligand specificity of the human 5-HT2B receptor (5-HT > ritanserin > SB 204741 > spiperone) was distinct from that of the human 5-HT2A (ritanserin > spiperone > 5-HT > SB 204741) and 5-HT2C (ritanserin > 5-HT > spiperone = SB 204741) receptors.	Spiperone	165-174	5-hydroxytryptamine receptor 2B	Homo sapiens	36-51
7582481-15	1995	The ligand specificity of the human 5-HT2B receptor (5-HT > ritanserin > SB 204741 > spiperone) was distinct from that of the human 5-HT2A (ritanserin > spiperone > 5-HT > SB 204741) and 5-HT2C (ritanserin > 5-HT > spiperone = SB 204741) receptors.	Spiperone	165-174	5-hydroxytryptamine receptor 2B	Homo sapiens	36-51
7620887-5	1995	The effects of all agonists were completely or partially blocked by the 5-HT1A and 5-HT2 receptor antagonist spiperone (spiroperidol hydrochloride) while selective 5-HT2 receptor antagonists were ineffective.	Spiperone	109-118	5-hydroxytryptamine receptor 1A	Homo sapiens	72-97
7620887-5	1995	The effects of all agonists were completely or partially blocked by the 5-HT1A and 5-HT2 receptor antagonist spiperone (spiroperidol hydrochloride) while selective 5-HT2 receptor antagonists were ineffective.	Spiperone	109-118	5-hydroxytryptamine receptor 2A	Homo sapiens	83-97
7620898-3	1995	Spiperone and MDL 100,507, antagonists that bind with 300- to 1000-fold higher affinity to 5-HT2A receptors, blocked 5-HT-induced phosphoinositide hydrolysis in hippocampi of 7-day-old, but not 21-day-old, rats.	Spiperone	0-9	5-hydroxytryptamine receptor 2A	Rattus norvegicus	91-97
7708749-2	1995	Both agonists and antagonists specific for various serotonin (5-hydroxytryptamine, 5HT) receptor subtypes interacted directly with alpha 2 beta 4 nAcChoRs: 5HT, (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin, methysergide, spiperone, and ketanserin reversibly reduced the amplitude of AcCho currents and accelerated their decay.	Spiperone	221-230	MGC75582, possible similarity to act2 S homeolog	Xenopus laevis	131-138
7766866-1	1995	Intracerebroventricular infusion of an all-phosphorothioate antisense oligodeoxynucleotide targeted at the rat dopamine D3 receptor mRNA (10 micrograms h-1, 5 days) resulted in a significant reduction (19%) of the binding of the [D2 + D3] ligand [3H]spiperone in the limbic forebrain, where D3 receptors are relatively abundant, but not in caudate-putamen, where D3 receptors are sparse.	Spiperone	250-259	dopamine receptor D3	Rattus norvegicus	111-131
7617670-3	1995	D1 and D2 receptor analysis via radioligand binding using [3H]-SCH 23390 and [3H]-spiperone, correspondingly, showed an increase of D2 receptor density with decreased affinity to D2 ligand in striatum of mutants: both Bmax and Kd were markedly higher.	Spiperone	82-91	dopamine receptor D2	Mus musculus	7-18
7617670-3	1995	D1 and D2 receptor analysis via radioligand binding using [3H]-SCH 23390 and [3H]-spiperone, correspondingly, showed an increase of D2 receptor density with decreased affinity to D2 ligand in striatum of mutants: both Bmax and Kd were markedly higher.	Spiperone	82-91	dopamine receptor D2	Mus musculus	132-143
7777184-0	1995	Differential effects of [3H]nemonapride and [3H]spiperone binding on human dopamine D4 receptors.	Spiperone	44-57	Rho GDP dissociation inhibitor beta	Homo sapiens	84-86
7777184-1	1995	We compared some binding parameters of [3H]nemonapride and [3H]spiperone in human dopamine D4 (hD4) receptors with three different numbers of tandem repeat units.	Spiperone	63-72	Rho GDP dissociation inhibitor beta	Homo sapiens	91-93
7813543-9	1994	This suggests that [3H]spiroperidol binding sites in the pulmonary artery probably belong to the dopamine D2 receptor subtype.	Spiperone	23-35	dopamine receptor D2	Homo sapiens	97-117
7830089-0	1995	[3H]nemonapride and [3H]spiperone label equivalent numbers of D2 and D3 dopamine receptors in a range of tissues and under different conditions.	Spiperone	24-33	dopamine receptor D2	Homo sapiens	62-90
8773241-6	1995	The 5-HT2/5-HT1A antagonist spiperone, in small doses, also blocked the transient inhibitory phases in addition to the excitatory effects.	Spiperone	28-37	5-hydroxytryptamine receptor 1A	Rattus norvegicus	10-16
8001587-4	1994	The KD values for the binding of the dopamine antagonist [3H]spiperone were calculated to be 1.6 nM for the D2S receptor alone and 1.9 nM for the STE2-D2S chimaera.	Spiperone	57-70	alpha-factor pheromone receptor STE2	Saccharomyces cerevisiae S288C	146-150
7777184-2	1995	Although both of the radioligands showed similar affinity constants for each hD4 receptor variant, the maximal number of binding sites labeled by [3H]nemonapride was approximately 1.35-fold higher than that by [3H]-spiperone for all variants.	Spiperone	215-224	Rho GDP dissociation inhibitor beta	Homo sapiens	77-80
7777184-3	1995	Estimated Ki values for the inhibition of [3H]nemonapride binding by a series of dopaminergic ligands were highly correlated to respective values obtained for the inhibition of [3H]spiperone binding to each hD4 receptor.	Spiperone	181-190	Rho GDP dissociation inhibitor beta	Homo sapiens	207-210
7996480-5	1994	Because spiperone has a higher affinity for 5-HT2A than 5-HT2C receptors, these data suggest that DOI stimulates ACTH secretion through 5-HT2A receptors.	Spiperone	8-17	5-hydroxytryptamine receptor 2A	Rattus norvegicus	44-50
7996480-5	1994	Because spiperone has a higher affinity for 5-HT2A than 5-HT2C receptors, these data suggest that DOI stimulates ACTH secretion through 5-HT2A receptors.	Spiperone	8-17	5-hydroxytryptamine receptor 2A	Rattus norvegicus	136-142
7898773-4	1994	5-HT2A receptors: risperidone (9.07) > spiperone > chlorpromazine > clozapine > thioridazine = fluphenazine > haloperidol (6.03).	Spiperone	42-51	5-hydroxytryptamine receptor 2A	Rattus norvegicus	0-6
7898773-5	1994	5-HT2C receptors: clozapine (7.19) > chlorpromazine > risperidone > thioridazine > fluphenazine > spiperone > haloperidol (< 4.00).	Spiperone	113-122	5-hydroxytryptamine receptor 2C	Rattus norvegicus	0-6
7965707-4	1994	On the other hand, spiperone (5-HT1A/5-HT2A/D2 antagonist) pretreatment significantly attenuated DOM-induced increases in ACTH but not corticosterone.	Spiperone	19-28	5-hydroxytryptamine receptor 1A	Rattus norvegicus	30-36
7965707-4	1994	On the other hand, spiperone (5-HT1A/5-HT2A/D2 antagonist) pretreatment significantly attenuated DOM-induced increases in ACTH but not corticosterone.	Spiperone	19-28	5-hydroxytryptamine receptor 2A	Rattus norvegicus	37-43
8035308-6	1994	On the other hand, spiperone (5-HT1A/5-HT2A/D2 antagonist) pretreatment significantly attenuated DOM-induced hyperthermia but accentuated DOM-induced hypophagia.	Spiperone	19-28	5-hydroxytryptamine receptor 1A	Rattus norvegicus	30-36
8035308-6	1994	On the other hand, spiperone (5-HT1A/5-HT2A/D2 antagonist) pretreatment significantly attenuated DOM-induced hyperthermia but accentuated DOM-induced hypophagia.	Spiperone	19-28	5-hydroxytryptamine receptor 2A	Rattus norvegicus	37-43
7969810-6	1994	8-OH-DPAT induced depression of the reflex (IC50 0.85, 0.7-1.0 microM, geometric mean and 95% confidence limits) was blocked by spiperone (1 microM, apparent pA2 6.3) suggesting mediation via 5-HT1A receptors.	Spiperone	128-137	5-hydroxytryptamine receptor 1A	Rattus norvegicus	192-198
7969811-4	1994	The 5-HT1A antagonists, (-)pindolol, (-)propranolol and spiperone, inhibited the effect of 8-OH-DPAT on wr-RSA.	Spiperone	56-65	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
7981639-3	1994	Spiperone (1 microM) and sulpiride (1 microM) were used to displace [125I]LSD binding from 5-HT2A and D2 binding sites, respectively.	Spiperone	0-9	5-hydroxytryptamine receptor 2A	Rattus norvegicus	91-97
8014859-4	1994	Spiperone (0.2 microM), a 5-HT1A/5-HT2 antagonist, blocks the effect of both LSD and 5-HT.	Spiperone	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	26-32
8014862-6	1994	injection of the 5-HT1A agonist (+)-hydroxy-2-(di-N-propylamino)tetralin (0.25-2 micrograms), with the maximal effect occurring at 0.5 micrograms, which can be prevented by the 5-HT1A antagonist spiperone (25 micrograms i.t.).	Spiperone	195-204	5-hydroxytryptamine receptor 1A	Rattus norvegicus	17-23
7916464-3	1994	In contrast, in striatal membranes the Bmax values of both [3H]-SCH 23390 and [3H]-spiroperidol bindings to D1 and D2 dopamine receptors were decreased.	Spiperone	83-95	dopamine receptor D2	Rattus norvegicus	108-136
7913396-8	1994	The 5-HT1A/2 antagonist, spiperone, antagonized the effects of 5-HT on synaptic and glutamate potentials.	Spiperone	25-34	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
8014862-12	1994	could be attenuated dose-dependently either by the 5-HT1A antagonist spiperone (5 and 25 micrograms i.t.)	Spiperone	69-78	5-hydroxytryptamine receptor 1A	Rattus norvegicus	51-57
8190100-3	1994	This effect of 5-HT was blocked by 10 nM ketanserin as well as by 10 nM spiperone, indicating a response mediated by the 5-HT2A receptor subtype.	Spiperone	72-81	5-hydroxytryptamine receptor 2A	Homo sapiens	121-136
7907870-4	1994	The 5-HT1A receptor antagonist spiperone shifted the concentration-response curve of idazoxan to the right in a parallel manner.	Spiperone	31-40	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
8275340-4	1994	8-OH-DPAT blockade of this nicotine effect was reversed by spiperone, a 5-HT1A/2 antagonist.	Spiperone	59-68	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	72-78
8302284-1	1994	P-type Ca2+ channels in cerebellar Purkinje neurons and N-type Ca2+ channels in sympathetic neurons were found to be inhibited by D2 dopamine receptor antagonists with diverse structures, including phenothiazines (chlorpromazine and thioridazine), diphenylbutylpiperidines (fluspirilene and pimozide), butyrophenones (haloperidol and spiperone), and a piperazine (fluphenazine).	Spiperone	334-343	dopamine receptor D2	Homo sapiens	130-150
8139701-1	1994	The intrastriatal injection of neurotensin (10 pg/mouse) elicited vigorous contralateral rotations which were not affected by disruption of dopaminergic transmission using 6-OHDA lesion of the striatum or systemic administration of spiroperidol (0.03 mg/kg).	Spiperone	232-244	neurotensin	Mus musculus	31-42
8474032-3	1993	administration of the 5-hydroxytryptamine (5-HT)1A antagonist spiperone (1 mg/kg) antagonized the suppressant effect of microiontophoretic applications of 5-HT and of the selective 5-HT1A agonist 8-OH-DPAT on the firing activity of the rat dorsal raphe 5-HT neurons.	Spiperone	62-71	5-hydroxytryptamine receptor 1A	Rattus norvegicus	181-187
8121627-1	1993	The binding parameters of [3H]SCH 23390 and [3H]spiperone (radioligands for dopamine D1 and D2 receptors, respectively) were investigated in autopsied frontal cortex, caudate nucleus and globus pallidus/putamen of cirrhotic patients who died in hepatic coma as well as in age- and sex-matched controls.	Spiperone	48-57	dopamine receptor D1	Homo sapiens	76-104
8271204-11	1993	Spiperone reversibly antagonized the response to 5-HT and 8-OHDPAT (8-hydroxy-2-(di-n-propylamino)tetralin) mimicked the response indicating that the receptor activated was of the 5-HT1A subtype.	Spiperone	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	180-186
8516375-2	1993	Bulbectomy resulted in the increase of Bmax for [3H]spiperone binding with 5-HT2 receptors in FC in C57Bl/6j.	Spiperone	52-61	hypothermia due to alcohol sensitivity 2	Mus musculus	77-80
7682614-6	1993	Spiperone, propranolol and pindolol (mixed 5-HT1A and 5-HT1B antagonists) effectively reversed both the tail-flick facilitation and the antagonistic effect on morphine sulfate-induced antinociception produced by 8-OH-DPAT and 5-CT.	Spiperone	0-9	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	43-49
7682614-6	1993	Spiperone, propranolol and pindolol (mixed 5-HT1A and 5-HT1B antagonists) effectively reversed both the tail-flick facilitation and the antagonistic effect on morphine sulfate-induced antinociception produced by 8-OH-DPAT and 5-CT.	Spiperone	0-9	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	54-60
8152532-7	1993	In contrast, spiperone (5-HT1A/2 receptors antagonist: 0.2 mg/kg, s.c.) only inhibited the increased acquisition induced by TFMPP.	Spiperone	13-22	5-hydroxytryptamine receptor 1A	Rattus norvegicus	24-30
8152532-10	1993	The acquisition of conditioned avoidance induced by TFMPP, which was blocked by ketanserin, mianserin and spiperone but not by pindolol, suggests the involvement of 5-HT1C/2 receptors in the action of TFMPP.	Spiperone	106-115	5-hydroxytryptamine receptor 2C	Rattus norvegicus	165-171
7907025-5	1993	Spiperone, spiperone plus propranolol, LY 53857, ketanserin and propranolol antagonised the pressor effects of DOI suggesting the stimulation of both 5-HT2 and 5-HT1C receptors.	Spiperone	0-9	5-hydroxytryptamine receptor 2C	Rattus norvegicus	160-166
7907025-5	1993	Spiperone, spiperone plus propranolol, LY 53857, ketanserin and propranolol antagonised the pressor effects of DOI suggesting the stimulation of both 5-HT2 and 5-HT1C receptors.	Spiperone	11-20	5-hydroxytryptamine receptor 2C	Rattus norvegicus	160-166
7907025-6	1993	Propranolol and spiperone plus propranolol suppressed the weak increase in heart rate induced by DOI, indicating the stimulation of 5-HT1C receptors.	Spiperone	16-25	5-hydroxytryptamine receptor 2C	Rattus norvegicus	132-138
7690361-5	1993	This DA-inhibited Ca2+ influx was reversed by spiperone, a D2-dopamine receptor antagonist.	Spiperone	46-55	dopamine receptor D2	Homo sapiens	59-79
8229069-6	1993	In C3H mice, methysergide, mianserin, ketanserin, and spiperone significantly decreased the TRH content in all regions of the spinal cord, while 3 alpha-tropanyl-1H-indole-3-carboxylic acid ester (ICS205-930) did not affect it.	Spiperone	54-63	thyrotropin releasing hormone	Mus musculus	92-95
8355253-4	1993	Although the neuroleptic agent spiperone binds at D2 dopamine receptors and 5-HT1A serotonin receptors, (a) it displays about a 1000-fold selectivity for 5-HT2 versus 5-HT1C sites and (b) it has been used as a "5-HT2-selective" antagonist.	Spiperone	31-40	5-hydroxytryptamine receptor 2C	Rattus norvegicus	167-173
8103326-1	1993	The D2 dopamine receptor expressed in the MMQ cell line was characterized by saturation binding using the D2 dopamine radioligand [3H]spiperone.	Spiperone	134-143	dopamine receptor D2	Rattus norvegicus	4-24
8223911-6	1993	Spiperone (30 nM), which binds weakly to 5-HT1C receptors but has a high affinity for 5-HT2 receptors, did not inhibit the actions of serotonin.	Spiperone	0-9	5-hydroxytryptamine receptor 2C	Rattus norvegicus	41-47
8461029-4	1993	For both radioligands the binding sites labelled have the properties of 5HT1A receptors and most antagonists show roughly equal affinities for the receptors labelled by either [3H]8-OH-DPAT or [3H]spiperone.	Spiperone	197-206	5-hydroxytryptamine receptor 1A	Homo sapiens	72-77
8492912-8	1993	Spiperone (1 mg/kg), a mixed serotonin2 and dopamine D2 antagonist, also attenuated the Fos response in the same regions, but had the effect of inducing Fos expression on its own in other extrapyramidal brain regions.	Spiperone	0-9	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	88-91
8492912-8	1993	Spiperone (1 mg/kg), a mixed serotonin2 and dopamine D2 antagonist, also attenuated the Fos response in the same regions, but had the effect of inducing Fos expression on its own in other extrapyramidal brain regions.	Spiperone	0-9	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	153-156
8449227-4	1993	Subnanomolar concentrations of methysergide, ritanserin and spiperone, but not ICS 205-930, attenuated the 5-HT enhancement, compatible with 5-HT2, but not 5-HT1 or 5-HT3 receptor subtype involvement.	Spiperone	60-69	5-hydroxytryptamine receptor 3A	Rattus norvegicus	165-179
8422910-1	1993	Recombinant cell lines expressing D2 and D3 dopamine receptor isoforms have been used to study coupling of these receptors to G-proteins from the effects of GTP to reduce agonist binding affinities in agonist/[3H]spiperone competition experiments.	Spiperone	213-222	D(3) dopamine receptor	Cricetulus griseus	41-61
8243108-4	1993	5-HT1C sites labelled with [3H]-mesulergine showed a distinct regional distribution: brainstem > diencephalon > cortex > hippocampus > cerebellum, constituting 65, 70, 31, 70, and 73% of total sites labelled by [3H]-mesulergine in the absence of 20 nM spiperone to block 5-HT2 sites, respectively.	Spiperone	264-273	5-hydroxytryptamine receptor 2C	Rattus norvegicus	0-6
8423526-6	1993	Five structurally distinct 5-HT2-receptor antagonists (ketanserin, cisapride, spiperone, MDL11939, ICI169369) blocked 5-HT-induced contraction with antagonist dissociation constants similar to reported 5-HT2-receptor affinities.	Spiperone	78-87	5-hydroxytryptamine receptor 2A	Homo sapiens	27-41
7870997-7	1993	The preference reducing effect of ipsapirone (20 mg/kg, PO) was completely blocked by the nonselective 5-HT1A antagonist spiperone (0.05 mg/kg, SC).	Spiperone	121-130	5-hydroxytryptamine receptor 1A	Rattus norvegicus	103-109
1585262-1	1992	In the presence of spiperone to block the 5-HT1A-mediated inhibition of pyramidal cell activity, 5-hydroxytryptamine (serotonin, 5-HT) produces a rapid transient increase in amplitude of the extracellularly recorded population spike from area CA1 of the hippocampus.	Spiperone	19-28	5-hydroxytryptamine receptor 1A	Rattus norvegicus	42-48
1360027-4	1992	The affinity and selectivity of these compounds for D-1 and D-2 subtypes was determined in radioligand competition assays for the DA receptors of rat striatum membranes using [3H]SCH 23390 (D-1 selective) and [3H]spiperone (D-2 selective) as radioligands.	Spiperone	213-222	solute carrier family 3 member 1	Rattus norvegicus	52-63
1358662-5	1992	The apparently different dopamine D2 receptor densities revealed by these two types of 3H-ligands (i.e. [3H]spiperone and the [3H]benzamides), therefore, arise from an inherent property of the dopamine D2 receptor protein.	Spiperone	108-117	dopamine receptor D2	Homo sapiens	25-45
1358662-5	1992	The apparently different dopamine D2 receptor densities revealed by these two types of 3H-ligands (i.e. [3H]spiperone and the [3H]benzamides), therefore, arise from an inherent property of the dopamine D2 receptor protein.	Spiperone	108-117	dopamine receptor D2	Homo sapiens	193-213
1402901-4	1992	The melatonin-evoked rise in the retinal NAT activity was counteracted by two dopamine D2 receptor agonists, quinpirole and apomorphine, and prevented by the dopamine D2 receptor blocker spiroperidol, and by an inhibitor of dopamine synthesis, alpha-methyl-p-tyrosine.	Spiperone	187-199	arylamine N-acetyltransferase, liver isozyme	Gallus gallus	41-44
1403796-9	1992	The selective 5-HT1A antagonist BMY 7378 and the 5-HT1A/2 antagonist spiperone were competitive in area CA1, but insurmountable in area CA3.	Spiperone	69-78	5-hydroxytryptamine receptor 1A	Homo sapiens	49-55
1403796-9	1992	The selective 5-HT1A antagonist BMY 7378 and the 5-HT1A/2 antagonist spiperone were competitive in area CA1, but insurmountable in area CA3.	Spiperone	69-78	carbonic anhydrase 1	Homo sapiens	104-107
1403796-9	1992	The selective 5-HT1A antagonist BMY 7378 and the 5-HT1A/2 antagonist spiperone were competitive in area CA1, but insurmountable in area CA3.	Spiperone	69-78	carbonic anhydrase 3	Homo sapiens	136-139
1446239-11	1992	This response, as well as the 5HT mediated suppression are blocked by the application of spiperone, a 5HT1A antagonist.	Spiperone	89-98	5-hydroxytryptamine receptor 1A	Homo sapiens	102-107
1323650-12	1992	Spiperone, which acts as a pure 5-HT1A antagonist at raphe 5-HT1A receptors, blocked the action of S 14671.	Spiperone	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	32-38
1578282-5	1992	(+/-)-Cyanopindolol (100 nM), a 5-HT1B antagonist, blocked the effect of 5-HT (10 microM); spiperone (1 microM), which is an antagonist at 5-HT1A and 5-HT2 receptors, had no effect.	Spiperone	91-100	5-hydroxytryptamine receptor 1B	Rattus norvegicus	32-38
1578282-5	1992	(+/-)-Cyanopindolol (100 nM), a 5-HT1B antagonist, blocked the effect of 5-HT (10 microM); spiperone (1 microM), which is an antagonist at 5-HT1A and 5-HT2 receptors, had no effect.	Spiperone	91-100	5-hydroxytryptamine receptor 1A	Rattus norvegicus	139-145
1422575-9	1992	Spiperone (0.2 and 1 mg kg-1, s.c.), a 5-HT2/dopamine D2 receptor antagonist which has low affinity for 5-HT1C receptors, also antagonized the effect of DOI (0.5 mg kg-1, s.c.).	Spiperone	0-9	5-hydroxytryptamine receptor 2C	Rattus norvegicus	104-110
1323650-12	1992	Spiperone, which acts as a pure 5-HT1A antagonist at raphe 5-HT1A receptors, blocked the action of S 14671.	Spiperone	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	59-65
1421122-5	1992	Ketanserin (5-HT2 receptor family antagonist) and spiperone (5-HT1A and 5-HT2 receptor family antagonist) blocked the current in a concentration dependent manner.	Spiperone	50-59	5-hydroxytryptamine receptor 1A	Rattus norvegicus	61-67
1585262-1	1992	In the presence of spiperone to block the 5-HT1A-mediated inhibition of pyramidal cell activity, 5-hydroxytryptamine (serotonin, 5-HT) produces a rapid transient increase in amplitude of the extracellularly recorded population spike from area CA1 of the hippocampus.	Spiperone	19-28	carbonic anhydrase 1	Rattus norvegicus	243-246
1585262-3	1992	Most of the experiments were conducted in the presence of spiperone to block the 5HT1A hyperpolarization.	Spiperone	58-67	5-hydroxytryptamine receptor 1A	Rattus norvegicus	81-86
1834494-12	1991	The PRL promoter repression mediated by each receptor isoform had appropriate pharmacology: the specific D2R agonist, quinpirole, yielded results similar to ECR, and the ECR repression was reversed by the dopamine antagonist spiperone.	Spiperone	225-234	prolactin	Rattus norvegicus	4-7
1320445-9	1992	The 5-HT1C/2 antagonist ketanserin and the 5-HT1A/2 antagonist spiperone significantly attenuated the 5-HT-induced depression of NMDA-depolarizations.	Spiperone	63-72	5-hydroxytryptamine receptor 1A	Homo sapiens	43-49
1839137-2	1991	Agents that have high and selective affinity for the 5-HT1A site such as 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and N,N-dipropyl-5-carboxamidotryptamine (DP5CT) inhibited the responses to field stimulation in guinea-pig ileum preparations; the inhibitory effects were antagonized by methiothepin and spiperone, consistent with effects at the 5-HT1A site.	Spiperone	312-321	5-hydroxytryptamine receptor 1A	Cavia porcellus	53-59
1686620-7	1991	Spiroperidol and aminophylline given alone at different times of day under light conditions stimulated NAT activity, and their effects were mainly additive when given in combination.	Spiperone	0-12	arylamine N-acetyltransferase, liver isozyme	Gallus gallus	103-106
1920135-7	1991	Low doses of spiperone (0.01 and 0.1 mg/kg, s.c.) significantly reduced the renin response to DOI.	Spiperone	13-22	renin	Rattus norvegicus	76-81
1920135-8	1991	Because spiperone has a higher affinity for 5-HT2 than 5-HT1C receptors, these data suggest that DOI stimulates renin secretion through 5-HT2 receptors.	Spiperone	8-17	renin	Rattus norvegicus	112-117
1861158-11	1991	Immunostaining of cells by the anti-idiotypic antibodies was inhibited by appropriate pharmacological agents: immunostaining of cells expressing 5-HT1C receptors was blocked by mesulergine (but not ketanserin, 8-OH-DPAT, or spiperone), whereas that of cells expressing 5-HT2 receptors was blocked by ketanserin or spiperone (but not mesulergine or 8-OH-DPAT).	Spiperone	224-233	5-hydroxytryptamine receptor 2C	Homo sapiens	145-151
1861158-11	1991	Immunostaining of cells by the anti-idiotypic antibodies was inhibited by appropriate pharmacological agents: immunostaining of cells expressing 5-HT1C receptors was blocked by mesulergine (but not ketanserin, 8-OH-DPAT, or spiperone), whereas that of cells expressing 5-HT2 receptors was blocked by ketanserin or spiperone (but not mesulergine or 8-OH-DPAT).	Spiperone	314-323	5-hydroxytryptamine receptor 2C	Homo sapiens	145-151
1531364-5	1992	Examination of N-substituted analogues of spiperone may provide insights into the topography of the antagonist binding region of the 5-HT2 receptor.	Spiperone	42-51	5-hydroxytryptamine receptor 2A	Homo sapiens	133-147
1387164-5	1992	Chronic injection with other drugs such as 1-propranolol, (+/-) pindolol and spiperone (5-HT1A and 5-HT2 antagonists), methysergide (5-HT1 and 5-HT2 antagonist), and agonists and antagonists at various other 5-HT receptors also had no effect on binding parameters.	Spiperone	77-86	5-hydroxytryptamine receptor 1A	Rattus norvegicus	88-94
1311807-2	1992	Both [3H]DOB and [3H]spiperone high affinity binding sites were present in membranes of sense but not of antisense, 5-HT2 receptor cDNA transfected cells.	Spiperone	21-30	5-hydroxytryptamine receptor 2A	Homo sapiens	116-130
1311807-5	1992	The ability of different antagonists to inhibit 5-HT-stimulated turnover of PI bore a direct relationship with their potency to inhibit 5-HT2 receptor binding in cells transfected with 5-HT2 receptor cDNA (spiperone greater than ketanserin greater than ritanserin greater than mianserin greater than haloperidol).	Spiperone	206-215	5-hydroxytryptamine receptor 2A	Homo sapiens	136-150
1311807-5	1992	The ability of different antagonists to inhibit 5-HT-stimulated turnover of PI bore a direct relationship with their potency to inhibit 5-HT2 receptor binding in cells transfected with 5-HT2 receptor cDNA (spiperone greater than ketanserin greater than ritanserin greater than mianserin greater than haloperidol).	Spiperone	206-215	5-hydroxytryptamine receptor 2A	Homo sapiens	185-199
1534874-7	1992	Similarly, only the 5-HT1A antagonists, spiroxatrine and spiperone, attenuated the hyperalgesia induced by intradermally injected serotonin.	Spiperone	57-66	5-hydroxytryptamine receptor 1A	Rattus norvegicus	20-26
1776132-5	1991	The 5-HT antagonist spiperone, which has a much higher affinity for 5-HT2 receptors than for 5-HT1C receptors, blocked the excitatory effect of 5-HT at lower concentrations in interneurons (IC50 = 31 nM) than in pyramidal cells (IC50 = 2.1 microM).	Spiperone	20-29	5-hydroxytryptamine receptor 2C	Rattus norvegicus	93-99
1776132-9	1991	In that both spiperone and ritanserin have higher affinity for 5-HT2 receptors than for 5-HT1C receptors and LY 53857 has a higher affinity for 5-HT1C receptors than for 5-HT2 receptors, these data suggest that in piriform cortex excitatory effects of 5-HT are mediated by 5-HT1C receptors in pyramidal cells an by 5-HT2 receptors in interneurons.	Spiperone	13-22	5-hydroxytryptamine receptor 2C	Rattus norvegicus	88-94
1679343-1	1991	Orthovanadate (in the micromolar range) inhibits the high-affinity binding of the D2 dopamine receptor to specific agonists (apomorphine and N-propylnorapomorphine), while it does not affect the binding to D2 antagonists (spiperone and haloperidol).	Spiperone	222-231	dopamine receptor D2	Homo sapiens	82-102
1893914-5	1991	MDL 73005EF and the 5-HT1A/2 receptor antagonist spiperone (both 3 microM) reduced the frequency and amplitude of spontaneous inhibitory (bicuculline-sensitive) postsynaptic potentials.	Spiperone	49-58	5-hydroxytryptamine receptor 1A	Rattus norvegicus	20-26
2068047-2	1991	The early availability of specific antagonists for the serotonin-2 (5-HT2) receptor subtype (spiperone, ketanserin and ritanserin represented an important step towards the biochemical, physiological and, more recently, molecular characterization of 5-HT2 receptors in brain.	Spiperone	93-102	5-hydroxytryptamine receptor 2A	Homo sapiens	68-83
1826033-10	1991	Spiperone and spiroxatrine, D2 antagonists with high 5-HT1A affinity, also inhibited 8-OH-DPAT-induced STFs.	Spiperone	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	53-59
1826942-3	1991	Pretreatment with the 5-HT1A/D2 dopamine (DA) receptor antagonist spiperone or the D1 DA receptor antagonist SCH-23390 abolished the DPAT-induced preferences.	Spiperone	66-75	5-hydroxytryptamine receptor 1A	Rattus norvegicus	22-28
1670924-4	1991	These morphological changes were accompanied by the functional expression of D2 dopamine receptors as shown by the presence of a specific, saturable, and stereoselective high affinity binding for [3H]spiroperidol in epidermal growth factor-treated cells and by the fact that the selective D2 agonist quinpirole recovered the property to inhibit PRL secretion in the cell cultures exposed to the neurotrophic factor.	Spiperone	200-212	epidermal growth factor like 1	Rattus norvegicus	216-239
2069496-3	1991	The binding characteristics (Kd [binding affinity] and Bmax [number of binding sites]) of the D2 dopamine receptor were determined in the caudate nuclei of these brains using tritiated spiperone as the ligand.	Spiperone	185-194	dopamine receptor D2	Homo sapiens	94-114
1683291-6	1991	administration of the 5HT1A receptor antagonist spiperone.	Spiperone	48-57	5-hydroxytryptamine receptor 1A	Homo sapiens	22-36
1683291-7	1991	Similarly we have previously observed spiperone reversal of the sympatholytic effects of the 5-HT1A agonist 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) but failed to affect nerve activity when given alone.	Spiperone	38-47	5-hydroxytryptamine receptor 1A	Homo sapiens	93-99
1826198-1	1991	In summary then these data suggest that butyrophenones such as spiperone and substituted benzamides such as sulpiride interact with different groups at the active site of the D2 dopamine receptor.	Spiperone	63-72	dopamine receptor D2	Bos taurus	175-195
1946036-2	1991	[3H]5-HT binding to 5-HT1A and non-5-HT1A sites, of high and low affinity for spiperone, respectively, was investigated in three parts of the hippocampus: dorsal, medial and ventral.	Spiperone	78-87	5-hydroxytryptamine receptor 1A	Rattus norvegicus	20-26
1946036-2	1991	[3H]5-HT binding to 5-HT1A and non-5-HT1A sites, of high and low affinity for spiperone, respectively, was investigated in three parts of the hippocampus: dorsal, medial and ventral.	Spiperone	78-87	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-41
2178032-4	1990	The effects of ipsapirone were reversed by the 5-HT1A antagonist spiperone.	Spiperone	65-74	5-hydroxytryptamine receptor 1A	Homo sapiens	47-53
2243353-1	1990	The 5-HT2 (serotonin) receptor has traditionally been labeled with antagonist radioligands such as [3H]ketanserin and [3H]spiperone, which label both agonist high-affinity (guanyl nucleotide-sensitive) and agonist low-affinity (guanyl nucleotide-insensitive) states of this receptor.	Spiperone	122-131	5-hydroxytryptamine receptor 2A	Rattus norvegicus	4-30
2148726-6	1990	Pindolol, spiperone, spiroxatrine and NAN-190 all have a high affinity for the 5-HT1A receptor.	Spiperone	10-19	5-hydroxytryptamine receptor 1A	Rattus norvegicus	79-85
2144583-1	1990	A series of group specific modifying reagents were tested for their effects on [3H]spiperone binding to brain D2 dopamine receptors to identify amino acid residues at the binding site of the D2 dopamine receptor that are critical for ligand binding.	Spiperone	79-92	dopamine receptor D2	Homo sapiens	110-130
2144583-9	1990	It is concluded that the D2 dopamine receptor binding site contains separate but over-lapping binding regions for antagonists such as spiperone and substituted benzamide drugs.	Spiperone	134-143	dopamine receptor D2	Homo sapiens	25-45
1695244-8	1990	The dopamine-mediated suppression of activity was significantly inhibited by pertussis toxin and by spiperone and sulpiride, both D2-dopamine receptor antagonists, but not by SCH 23390, a D1-dopamine receptor blocker, or antagonists of alpha-adrenergic, beta-adrenergic, or serotonergic receptors.	Spiperone	100-109	dopamine receptor D2	Gallus gallus	130-150
2143386-1	1990	The D1 and D2 dopamine receptors have been biochemically characterized using specific probes based on the subtype selective antagonists SCH 23390 and spiperone, respectively.	Spiperone	150-159	dopamine receptor D2	Rattus norvegicus	4-32
2208388-2	1990	These derivatives were tested for their ability to displace [3H]spiperone from its specific dopamine D-2 receptor.	Spiperone	60-73	dopamine receptor D2	Homo sapiens	92-113
2164094-11	1990	Consistent with its low potency at the 5-HT1c receptor, spiperone, a 5-HT2 and 5-HT1a antagonist, was a less effective antagonist of the phosphoinositide hydrolysis response than were ritanserin and mianserin.	Spiperone	56-65	5-hydroxytryptamine receptor 2C	Homo sapiens	39-45
2340447-8	1990	Spiperone, a nonspecific 5-HT antagonist, and ritanserin, a putative specific 5-HT2 receptor antagonist, depolarized CA1 neurons with little or no change in input resistance.	Spiperone	0-9	carbonic anhydrase 1	Homo sapiens	117-120
1688845-7	1990	Addition of GTP/NaCl increased the IC50 value for dopamine competition for [3H]spiperone binding by 2-fold, indicating that the D2-dopamine receptor interacts with one or more G-proteins.	Spiperone	75-88	dopamine receptor D2	Rattus norvegicus	128-148
2356002-5	1990	The hypersensitivity of the reflexes after pretreatment with buspirone was effectively blocked by the 5-HT1A selective antagonist spiperone, at all doses (0.001, 0.01, 0.1 and 1.0 mg/kg) tested.	Spiperone	130-139	5-hydroxytryptamine receptor 1A	Rattus norvegicus	102-108
1972893-7	1990	Subcutaneous injection of the 5-HT1a receptor antagonists spiroxatrine or spiperone inhibited the cardiovascular response to 8-OH-DPAT and 5-MU.	Spiperone	74-83	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	30-45
1696989-17	1990	Application of spiperone, the mixed 5-HT1A, 5-HT2 receptor antagonist, blocked the inward I5-HT.	Spiperone	15-24	5-hydroxytryptamine receptor 1A	Rattus norvegicus	36-42
1688845-10	1990	Antagonism of dopamine-induced inhibition of VIP-enhanced cAMP levels by spiperone, (+)-butaclamol, (-)-sulpiride, and SCH23390 occurred at concentrations expected from KI values for these antagonists at the D2-receptor and was stereoselective.	Spiperone	73-82	vasoactive intestinal peptide	Rattus norvegicus	45-48
2138222-4	1990	8-OH-DPAT (0.0625-4.0 micrograms) produced dose-dependent hypotension and bradycardia, which were antagonized by the 5-HT1A antagonists spiperone and spiroxatrine.	Spiperone	136-145	5-hydroxytryptamine receptor 1A	Homo sapiens	117-123
1967969-2	1990	This effect was antagonized by the antipsychotic drugs (APDs) clozapine (CLOZ) and spiperone (SPIP), with CLOZ displaying a greater potency in blocking DOI"s action in the mPFc.	Spiperone	83-92	complement factor properdin	Mus musculus	172-176
2137698-8	1990	The putative 5-HT1A autoreceptor antagonist spiperone reversed the cocaine-induced depression of firing rate in 64% of 5-HT neurons tested whereas receptor antagonists for dopamine D2 (haloperidol), 5-HT2 (ketanserin), gamma-aminobutyric acid (picrotoxin) and 5-HT1/beta-adrenergic (propranolol) were ineffective.	Spiperone	44-53	5-hydroxytryptamine receptor 1A	Rattus norvegicus	13-19
1967969-2	1990	This effect was antagonized by the antipsychotic drugs (APDs) clozapine (CLOZ) and spiperone (SPIP), with CLOZ displaying a greater potency in blocking DOI"s action in the mPFc.	Spiperone	94-98	complement factor properdin	Mus musculus	172-176
20504590-7	1990	Further, the 5-HT(1A) agonist effects of BMY 7378 were blocked by the 5-HT(1A) antagonist, spiperone.	Spiperone	91-100	5-hydroxytryptamine receptor 1A	Rattus norvegicus	13-20
2257905-9	1990	The effects of FFA were blocked by the 5-HT1a antagonist spiperone but not by the 5-HT2 antagonist mianserin.	Spiperone	57-66	5-hydroxytryptamine receptor 1A	Rattus norvegicus	39-45
2143754-1	1990	We synthesized a new spiperone derivative: iodoethylspiperone (IES) to perform dopamine D2 receptor exploration by SPECT.	Spiperone	21-30	dopamine receptor D2	Homo sapiens	79-99
20504590-7	1990	Further, the 5-HT(1A) agonist effects of BMY 7378 were blocked by the 5-HT(1A) antagonist, spiperone.	Spiperone	91-100	5-hydroxytryptamine receptor 1A	Rattus norvegicus	70-77
2234404-4	1990	The effects of serotonin on the inhibitory postsynaptic potentials are blocked by the 5-HT1a antagonist spiperone, and not by mianserin, a 5-HT2 antagonist.	Spiperone	104-113	5-hydroxytryptamine receptor 1A	Rattus norvegicus	86-92
2141111-6	1990	The changes in potential produced by low concentrations of serotonin and by these agonists were blocked by the 5-HT1A receptor antagonists spiperone and spiroxatrine.	Spiperone	139-148	5-hydroxytryptamine receptor 1A	Homo sapiens	111-126
2107558-4	1990	Proaversive effects were found with the mixed 5-HT1C/5-HT2 antagonists cyproheptadine and ritanserin; this effect was already reported for the mixed 5-HT1C/5-HT2 antagonists metergoline and mianserin and is opposite to the effects of the selective 5-HT2 antagonists ketanserin, pirenperone, trazodone and spiperone.	Spiperone	305-314	5-hydroxytryptamine receptor 2C	Rattus norvegicus	46-52
2381516-4	1990	The serotonin 1C receptor binding sites were visualized autoradiographically and quantified using [3H]mesulergine as ligand, in the presence of spiperone to block serotonin 1C receptors.	Spiperone	144-153	5-hydroxytryptamine receptor 2C	Rattus norvegicus	4-25
2568481-5	1989	Apomorphine-induced inhibition of retinal NAT activity was blocked by spiperone, a D2-dopamine receptor antagonist, but not by antagonists of D1-dopamine, alpha-1, alpha-2 and beta adrenergic receptors.	Spiperone	70-79	arylamine N-acetyltransferase, liver isozyme	Gallus gallus	42-45
35475118-8	2022	Therefore, Abemaciclib, Dasatinib and Spiperone are likely to be viable drug-candidate molecules that can block the interaction between the omicron spike protein and the host cellular receptor ACE2.	Spiperone	38-47	angiotensin converting enzyme 2	Homo sapiens	193-197
10720636-6	2000	The degree of haloperidol-induced catalepsy was thus proportional to the level of striatal dopamine D(2) receptor expression (0.50, 0.30 and 0.08 pmol/mg protein as measured at 0.25 nM [3H]spiperone for D(2)(+/+), D(2)(+/-) and D(2)(-/-) mice, respectively).	Spiperone	189-198	dopamine receptor D2	Mus musculus	91-113
2531146-4	1989	Specific dopamine D2-receptor binding was saturated with increasing concentrations of radioligand (specific activity range: 1-10,000 Ci/mmol), was stereospecifically blocked with (+)butaclamol (0.5 mg/kg), and showed only partial displacement with spiperone (200 micrograms/kg, i.v.	Spiperone	248-257	dopamine receptor D2	Homo sapiens	9-29
2532359-1	1989	Using rat genomic DNA, we have established a transfected mouse fibroblast cell line that expresses a spiperone binding site with the pharmacological characteristics of a D2 dopamine receptor.	Spiperone	101-110	dopamine receptor D2	Mus musculus	170-190
2531613-13	1989	Affinity-purified preparations maintain the ligand-binding characteristics of a dopamine D2 receptor as assessed by agonist and antagonist competition for [3H]spiperone binding.	Spiperone	159-168	dopamine receptor D2	Bos taurus	80-100
2573713-1	1989	The binding of D2-dopamine receptor ligand [3H]spiperone and selective D1-ligand [3H]SCH 23390 to the rat adrenal gland and striatum has been compared.	Spiperone	47-56	dopamine receptor D2	Rattus norvegicus	15-35
2526217-10	1989	The response to 8-hydroxy-2-(di-n-propylamino) tetralin was antagonized by pretreatment with the 5-HT1A antagonist spiperone (1 microM).	Spiperone	115-124	5-hydroxytryptamine receptor 1A	Rattus norvegicus	97-103
2568481-5	1989	Apomorphine-induced inhibition of retinal NAT activity was blocked by spiperone, a D2-dopamine receptor antagonist, but not by antagonists of D1-dopamine, alpha-1, alpha-2 and beta adrenergic receptors.	Spiperone	70-79	dopamine receptor D2	Gallus gallus	83-103
2495434-7	1989	Spiperone, a potent 5-HT1A antagonist, competitively antagonized 5-HT-mediated inhibition of forskolin-stimulated adenylyl cyclase activity in rat hippocampal membranes with a Kb value of 14 nM.	Spiperone	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	20-26
2797215-3	1989	The specific binding of 3H-raclopride in the striatum, defined as the difference in the accumulation in striatum and cerebellum 30 min after the injection was completely inhibited by the D-2 receptor antagonists spiperone and (+)-butaclamol [but not (-)-butaclamol] and the DA receptor agonist N-n-propylnorapomorphine.	Spiperone	212-221	dopamine receptor D2	Mus musculus	187-199
2566495-8	1989	The actions of 8-OH-DPAT and buspirone, but not of RU 24969 and idazoxan, were blocked by the 5-HT1A receptor antagonist, spiroperidol.	Spiperone	122-134	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	94-109
2522986-5	1989	The inhibitory effects of these two compounds were not additive and were prevented by 5-HT1A antagonists such as spiperone and dl-propranolol.	Spiperone	113-122	5-hydroxytryptamine receptor 1A	Rattus norvegicus	86-92
2546988-9	1989	Spiperone (1 microM), a selective 5-HT1A antagonist, blocked the 5-HT-induced inhibition of the fast e.p.s.p.	Spiperone	0-9	5-hydroxytryptamine receptor 1A	Oryctolagus cuniculus	34-40
2725702-6	1989	3) The increase in inositol phosphate production induced by 5-HT and other agonists was surmountably antagonised by mesulergine, ketanserin and spiperone with pKB values of 8.7, 6.7 and 5.3, respectively.	Spiperone	144-153	AKT serine/threonine kinase 1	Sus scrofa	159-162
2653594-3	1989	Spiperone, used as a 5-hydroxytryptamine1A (5-HT1A) antagonist, suppressed the inhibitory action of serotonin in 14 of 21 tests.	Spiperone	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	21-42
2653594-3	1989	Spiperone, used as a 5-hydroxytryptamine1A (5-HT1A) antagonist, suppressed the inhibitory action of serotonin in 14 of 21 tests.	Spiperone	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	44-50
3143721-7	1988	Agonist and antagonist ligands compete for [3H]spiperone binding to purified receptors in phospholipid vesicles with a rank order of potency and selectivity typical of a D2-dopamine receptor.	Spiperone	43-56	dopamine receptor D2	Bos taurus	170-190
2563751-6	1989	Pretreatment with centrally acting dopamine antagonists (spiperone or haloperidol) prevented the (+)-PHNO-induced changes in serum corticosterone, prolactin and brain catecholamines.	Spiperone	57-66	prolactin	Rattus norvegicus	147-156
2811600-5	1989	However, significant differences existed between the 5-HT1D and 5-HT1R sites for their Ki values for spiperone, spirilene (an analog of spiperone), metergoline, and methiothepin.	Spiperone	101-110	5-hydroxytryptamine receptor 1D	Oryctolagus cuniculus	53-59
2811600-5	1989	However, significant differences existed between the 5-HT1D and 5-HT1R sites for their Ki values for spiperone, spirilene (an analog of spiperone), metergoline, and methiothepin.	Spiperone	136-145	5-hydroxytryptamine receptor 1D	Oryctolagus cuniculus	53-59
2474769-13	1989	Spiperone, a 5-HT1A antagonist reversibly blocked the response.	Spiperone	0-9	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	13-19
2450105-4	1988	Inhibition of the [3H]spiperone binding by various butyrophenone derivatives displayed a specificity similar to that observed for the inhibition of [3H]spiperone binding to the D2-dopamine receptor.	Spiperone	18-31	dopamine receptor D2	Homo sapiens	177-197
3134891-5	1988	The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and spiroperidol, prevented the binding of phenoxybenzamine to calmodulin.	Spiperone	188-200	calmodulin 1	Homo sapiens	44-54
3134891-5	1988	The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and spiroperidol, prevented the binding of phenoxybenzamine to calmodulin.	Spiperone	188-200	calmodulin 1	Homo sapiens	247-257
2967702-2	1988	All the permanently uncharged dopamine analogs were found to bind to the D-2 dopamine receptor as evidenced by their abilities to inhibit significantly [3H]spiperone binding to striatal homogenates.	Spiperone	156-165	dopamine receptor D2	Homo sapiens	73-94
2967702-3	1988	However, the inhibition of [3H]spiperone binding by the uncharged dopamine analogs was incomplete and was almost abolished by the addition of NaCl (125 mM) to the incubation medium or by the addition of dopamine or quinpirole at a concentration that that saturates the high-affinity state of the D-2 dopamine receptor.	Spiperone	27-40	dopamine receptor D2	Homo sapiens	296-317
2969339-0	1988	Electrophysiological evidence that spiperone is an antagonist of 5-HT1A receptors in the dorsal raphe nucleus.	Spiperone	35-44	5-hydroxytryptamine receptor 1A	Homo sapiens	65-71
2969339-1	1988	The neuroleptic spiperone, which binds to 5-HT1A, 5-HT2 and dopamine (DA) receptors, was studied for its effects on serotonin (5-HT) and DA neurons in dorsal raphe nucleus and substantia nigra pars compacta, respectively.	Spiperone	16-25	5-hydroxytryptamine receptor 1A	Homo sapiens	42-48
2969339-3	1988	spiperone, but not LY53837 (a 5-HT2 antagonist), antagonized the inhibition induced by 5-HT1A agonists 8-hydroxy-dipropylaminotetralin (8-OH-DPAT) and buspirone in the dorsal raphe nucleus.	Spiperone	0-9	5-hydroxytryptamine receptor 1A	Homo sapiens	87-93
2969339-7	1988	It is concluded that spiperone is an antagonist of 5-HT1A receptors in the dorsal raphe nucleus.	Spiperone	21-30	5-hydroxytryptamine receptor 1A	Homo sapiens	51-57
2976671-7	1988	In addition, the 5-HT1A receptor antagonist, spiperone, inhibited the 5-HT syndrome elicited by 8-OH-DPAT, while the dopamine receptor antagonist, haloperidol, affected only the head weaving.	Spiperone	45-54	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	17-32
3390820-3	1988	Ketanserin, cyproheptadine, and spiperone [serotonin (5-HT) receptor blockers] inhibited or attenuated the antitumor effects of rTNF-alpha, but the other types of receptor blockers tested (histamine H1 and H2, adrenaline alpha and beta, dopamine, and acetylcholine receptor blockers) did not.	Spiperone	32-41	tumor necrosis factor	Rattus norvegicus	128-138
3390820-3	1988	Ketanserin, cyproheptadine, and spiperone [serotonin (5-HT) receptor blockers] inhibited or attenuated the antitumor effects of rTNF-alpha, but the other types of receptor blockers tested (histamine H1 and H2, adrenaline alpha and beta, dopamine, and acetylcholine receptor blockers) did not.	Spiperone	32-41	histamine receptor H1	Mus musculus	189-273
2907912-6	1988	SCH23390 plus spiperone treatment resulted in a significant increase in both D1 and D2 dopamine receptor densities.	Spiperone	14-23	dopamine receptor D2	Rattus norvegicus	84-104
2970974-7	1988	Blockade of the hyperphagia by spiperone suggests mediation by 5-HT1A rather than 5-HT1B receptors.	Spiperone	31-40	5-hydroxytryptamine receptor 1A	Rattus norvegicus	63-69
2450105-4	1988	Inhibition of the [3H]spiperone binding by various butyrophenone derivatives displayed a specificity similar to that observed for the inhibition of [3H]spiperone binding to the D2-dopamine receptor.	Spiperone	148-161	dopamine receptor D2	Homo sapiens	177-197
3402898-5	1988	The latter activity, induced by micromolar concentrations of 5-HT, was inhibited by spiperone at concentrations that block 5-HT1A binding.	Spiperone	84-93	5-hydroxytryptamine receptor 1A	Rattus norvegicus	123-129
3129281-14	1988	Stimulated PRL and GH release from freshly dispersed GH4C1 tumor cells was inhibited by BCR at concentrations from 0.1-10 nM, and spiroperidol reversed the inhibition.	Spiperone	130-142	prolactin	Rattus norvegicus	11-14
3357484-5	1988	The dissociation rate constant of the overall binding reaction, as determined by inducing the dissociation of [3H]spiperone from its binding sites by 1 microM (+)-butaclamol, was 0.92 X 10(-3) sec-1.	Spiperone	110-123	secretory blood group 1	Rattus norvegicus	193-198
2962888-3	1988	The exoglycosidase, neuraminidase, altered the electrophoretic mobility of the 94 kDa labeled band to 54 kDa with a slight modification in the binding affinity of [3H]spiperone.	Spiperone	167-176	neuraminidase 1	Homo sapiens	20-33
2966782-8	1988	The specific uptake at the D-2 dopamine receptor site was blocked by pretreatment with spiperone, a selective D-2 antagonist.	Spiperone	87-96	dopamine receptor D2	Rattus norvegicus	27-48
3402898-7	1988	Enzyme activation by drugs acting in the micromolar range was inhibited by spiperone (1 microM), suggesting a link between this activation and 5-HT1A sites.	Spiperone	75-84	5-hydroxytryptamine receptor 1A	Rattus norvegicus	143-149
2963964-1	1987	The affinity of a series of N,N-disubstituted 2-aminotetralins for the rat striatal D2 dopamine receptor labelled by [3H]spiperone has been determined.	Spiperone	121-130	dopamine receptor D2	Rattus norvegicus	84-104
2961340-4	1987	Binding to and activation of the D-2 dopamine receptor were measured by determining the abilities of the permanently charged dopamine analogs to inhibit [3H]spiperone binding to striatal homogenates and to inhibit K+-stimulated [3H]acetylcholine release from striatal slices respectively.	Spiperone	157-166	dopamine receptor D2	Homo sapiens	33-54
2960326-0	1987	Dopamine D2 receptor binding in adrenal medulla: characterization using [3H]spiperone.	Spiperone	76-85	dopamine receptor D2	Bos taurus	0-20
2960326-9	1987	These results suggest that [3H]spiperone may bind to a high-affinity D2 dopamine receptor in adrenal medulla.	Spiperone	31-40	dopamine receptor D2	Bos taurus	69-89
3683595-12	1987	Ketanserin, a 5-HT2 receptor antagonist, and spiperone, which blocks 5-HT2 and 5-HT1A but not 5-HT1B or 5-HT1C receptors, failed to antagonize the effect of 5-HT.	Spiperone	45-54	5-hydroxytryptamine receptor 1A	Rattus norvegicus	79-85
2958724-1	1987	Rats trained to intravenously self-administer cocaine hydrochloride on a fixed ratio-5 schedule were subjected to a series of systemic injections of the D1 dopamine receptor selective antagonist SCH 23390 and the D2 dopamine receptor selective antagonist spiperone.	Spiperone	255-264	dopamine receptor D2	Rattus norvegicus	213-233
2885709-5	1987	The receptor antagonists saralacin and spiperone blocked the angiotensin II and dopamine effects, respectively.	Spiperone	39-48	angiotensinogen	Rattus norvegicus	61-75
2959699-2	1987	The assay revealed that platelets possess a single population of specific binding sites for 125I-iodoLSD which have a high affinity for the 5-HT2 receptor antagonists, ketanserin and spiperone.	Spiperone	183-192	5-hydroxytryptamine receptor 2A	Homo sapiens	140-154
2956114-3	1987	The corticosterone and beta-END responses to 8-OH-DPAT were antagonized by spiperone and (-)-pindolol, both of which have been shown to have high affinity for the 5-HT1A binding site.	Spiperone	75-84	5-hydroxytryptamine receptor 1A	Rattus norvegicus	163-169
3610034-2	1987	In addition to antidepressant agents, some neuroleptic drugs including chlorpromazine (CPZ), spiperon, and cisflupentixol reduced the numbers of 5HT-2 receptor binding sites after 21 days treatment.	Spiperone	93-101	5-hydroxytryptamine receptor 2A	Homo sapiens	145-159
3808316-3	1987	[3H]-spiperone binding indicated an increase in D2-dopamine receptor density in the caudate nucleus.	Spiperone	5-14	dopamine receptor D2	Homo sapiens	48-68
3121842-2	1987	In unlesioned rats, chronic haloperidol treatment (15 days) resulted in an increase in D2-dopamine receptor density, as measured with [3H]spiperone, in the nucleus accumbens and in the caudate-putamen.	Spiperone	138-147	dopamine receptor D2	Rattus norvegicus	87-107
3496228-2	1987	The compound had an IC50 value of 51 nM at the 5HT1B recognition site as determined using the binding of [3H]5HT in the presence of 1 microM spiperone.	Spiperone	141-150	5-hydroxytryptamine receptor 1B	Homo sapiens	47-52
3577589-2	1987	The specific [3H]spiperone binding sites on prolactin (PRL)-secreting adenoma membranes were recognized as a dopamine receptor, based upon the data showing high affinity binding, saturability, specificity, temperature dependence, and reversibility.	Spiperone	17-26	prolactin	Homo sapiens	44-53
2883013-5	1987	Evidence suggests that the above action of 8-OH-DPAT is mediated by 5-HT1A receptors since it was antagonised by the 5-HT1A antagonist spiperone but not by the 5-HT2 antagonist ketanserin and was not mimicked by the 5-HT1B agonist RU 24969.	Spiperone	135-144	5-hydroxytryptamine receptor 1A	Rattus norvegicus	68-74
2883013-5	1987	Evidence suggests that the above action of 8-OH-DPAT is mediated by 5-HT1A receptors since it was antagonised by the 5-HT1A antagonist spiperone but not by the 5-HT2 antagonist ketanserin and was not mimicked by the 5-HT1B agonist RU 24969.	Spiperone	135-144	5-hydroxytryptamine receptor 1A	Rattus norvegicus	117-123
2883013-5	1987	Evidence suggests that the above action of 8-OH-DPAT is mediated by 5-HT1A receptors since it was antagonised by the 5-HT1A antagonist spiperone but not by the 5-HT2 antagonist ketanserin and was not mimicked by the 5-HT1B agonist RU 24969.	Spiperone	135-144	5-hydroxytryptamine receptor 1B	Rattus norvegicus	216-222
3815073-4	1987	The pharmacological profiles are distinct for the spiperone-insensitive 5-HT1B and 5-HT3 sites in both human and bovine cortex.	Spiperone	50-59	5-hydroxytryptamine receptor 1B	Homo sapiens	72-78
3507886-8	1987	Wethers receiving Spiperone had lowered (P less than .05) plasma DA and elevated (P less than .01) plasma PRL.	Spiperone	18-27	prolactin	Ovis aries	106-109
22158750-3	1987	The effects of 8-OH-DPAT on stress-induced anorexia were blocked by the 5-HT(1A) antagonist spiperone but not by the 5-HT(2) antagonist ketanserin.	Spiperone	92-101	5-hydroxytryptamine receptor 1A	Rattus norvegicus	72-79
2947981-3	1986	In the latter case, it was shown that 3H-5-HT binding to 5-HT1A sites corresponded to that displaceable by 0.1 microM 8-OH-DPAT or 1 microM spiperone.	Spiperone	140-149	5-hydroxytryptamine receptor 1A	Rattus norvegicus	57-63
3098885-4	1986	This decrease in tyrosinase activity was blocked by dopamine receptor antagonists, haloperidol or spiperone.	Spiperone	98-107	tyrosinase	Mus musculus	17-27
3794715-8	1987	Striatal D-2 dopamine receptor binding using [3H]spiperone as ligand was significantly reduced in 18-day-old animals as compared to ad libitum and pair-fed controls.	Spiperone	45-58	dopamine receptor D2	Homo sapiens	9-30
2944752-3	1986	The apparent affinity of 8-methoxy-3"-NAP-amino-PAT for the 5-HT1A binding sites was at least 20 times higher than for the other 5-HT receptor sites (5-HT2 and 5-HT3) or the dopamine-related [3H]spiperone and [3H]7-OH-DPAT binding sites.	Spiperone	195-204	5-hydroxytryptamine receptor 1A	Rattus norvegicus	60-66
3746296-6	1986	This incorporation could be blocked when membranes were incubated with 1 microM of several agents that have high affinity for 5-HT1A sites [5-HT, 8-hydroxy-2-(di-n-propylamino)tetraline, TVX Q 7821, spiperone, buspirone, d-lysergic acid diethylamide, metergoline].	Spiperone	199-208	5-hydroxytryptamine receptor 1A	Rattus norvegicus	126-132
2948500-1	1986	Five stable hybridomas have been obtained that secrete monoclonal antibodies against the D2-dopamine receptor-selective drug spiperone.	Spiperone	125-134	dopamine receptor D2	Mus musculus	89-109
2935410-4	1985	[3H]Mesulergine bound in pig choroid plexus and in rat cortex (besides binding to 5-HT2 sites in rat cortex) to the 5-HT1C recognition site characterized by high affinity for metergoline, mesulergine, 5-HT and methergine and low affinity for (-)21-009, ICYP, 8-OH-DPAT and spiroperidol.	Spiperone	273-285	5-hydroxytryptamine receptor 2C	Rattus norvegicus	116-122
3768735-0	1986	Cardiovascular and drinking responses elicited by central administration of angiotensin II: differential effects of GABA injected into the ventral tegmental area and spiperone injected into the nucleus accumbens.	Spiperone	166-175	angiotensinogen	Rattus norvegicus	76-90
2941422-7	1986	One-cycle affinity purification resulted in a recovery of 12% of the original membrane-bound dopamine D-2 receptor with a specific activity of 169,600 fmol/mg of protein as assayed with [3H]spiroperidol binding.	Spiperone	190-202	dopamine receptor D2	Bos taurus	93-114
2423604-6	1986	The concentration of 5-HTP producing the half-maximal effect = 4 X 10(-7) M. 5-HT suppression of IFN-gamma-induced Ia expression was antagonized by the 5-HT2 type receptor antagonists spiperone, ketanserin, and LY53857.	Spiperone	184-193	interferon gamma	Mus musculus	97-106
3018845-2	1986	Spiperone (ligand for 5-HT2 receptors) displaced [3H]TRH in a dose-dependent manner at micromolar concentrations.	Spiperone	0-9	thyrotropin releasing hormone	Rattus norvegicus	53-56
3494003-2	1986	Alkylation of the amide nitrogen in spiperone by NCA [18F]fluorobromoethane in the presence of a strong base gave 5 (Method A).	Spiperone	36-45	CEA cell adhesion molecule 4	Homo sapiens	49-52
2933490-5	1986	Spiperone and 8-hydroxy-2-(di-n-propylamino)tetralin, two compounds that discriminate [3H]5-HT binding to 5-HT1A and 5-HT1B sites, inhibited [3H]PAPP binding in accordance with their much higher affinities for the 5-HT1A receptor subtype.	Spiperone	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	106-112
2867462-8	1985	Interestingly, the selective 5-HT1A serotonin receptor antagonist, spiperone, and the selective 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino) tetraline, exhibit high affinity and monophasic competition for [3H]WB4101 but compete for multiple [3H]LSD 5-HT1 binding sites.	Spiperone	67-76	5-hydroxytryptamine receptor 1A	Rattus norvegicus	29-35
2867462-8	1985	Interestingly, the selective 5-HT1A serotonin receptor antagonist, spiperone, and the selective 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino) tetraline, exhibit high affinity and monophasic competition for [3H]WB4101 but compete for multiple [3H]LSD 5-HT1 binding sites.	Spiperone	67-76	5-hydroxytryptamine receptor 1A	Rattus norvegicus	96-102
3818319-9	1986	An assessment of 3HSp accumulation indicates that radiolabelled spiroperidol shows excellent potential for detecting PRL-secreting tumors of the pituitary.	Spiperone	64-76	prolactin	Rattus norvegicus	117-120
6083874-3	1984	Neurotensin, however, augmented the increase in [3H]spiroperidol binding caused by the haloperidol treatment in both the nucleus accumbens and striatum.	Spiperone	52-64	neurotensin	Rattus norvegicus	0-11
2933490-5	1986	Spiperone and 8-hydroxy-2-(di-n-propylamino)tetralin, two compounds that discriminate [3H]5-HT binding to 5-HT1A and 5-HT1B sites, inhibited [3H]PAPP binding in accordance with their much higher affinities for the 5-HT1A receptor subtype.	Spiperone	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	106-123
4085545-1	1985	The cholecystokinin (CCK) antagonist, proglumide, administered chronically (41.0-53.5 mg/kg per day, 14 days) to rats via osmotic mini-pumps, produced a significant 13% increase in the number of [3H]spiperone labeled binding sites (Bmax) in the striatum.	Spiperone	199-208	cholecystokinin	Rattus norvegicus	4-19
4009495-3	1985	The 5-HT2-selective receptor antagonist pirenperone (0.001-0.3 mg/kg) and the 5-HT2 receptor ligand spiperone (0.001-0.1 mg/kg) did not increase punished responding maintained by either event.	Spiperone	100-109	5-hydroxytryptamine receptor 2A	Homo sapiens	78-92
3160596-4	1985	Following addition of spiperone (1 microM) as a selective ligand for the putative 5-HT1A recognition site of [3H]5-HT, the displacement curve of RU 24969 underwent a leftward shift, whereas spiperone induced a shift to the right for the displacement curve of 8-OH-DPAT.	Spiperone	22-31	5-hydroxytryptamine receptor 1A	Rattus norvegicus	82-88
3160596-4	1985	Following addition of spiperone (1 microM) as a selective ligand for the putative 5-HT1A recognition site of [3H]5-HT, the displacement curve of RU 24969 underwent a leftward shift, whereas spiperone induced a shift to the right for the displacement curve of 8-OH-DPAT.	Spiperone	190-199	5-hydroxytryptamine receptor 1A	Rattus norvegicus	82-88
2988696-1	1985	The specific binding of [3H]spiperone, a D-2 dopamine receptor ligand, in in retinas from rabbits kept one week in constant light was significantly lower than in retinas from rabbits exposed to constant dark.	Spiperone	24-37	dopamine receptor D2	Homo sapiens	41-62
3158731-8	1985	In contrast, the total D-2 receptor population, [3H]spiperone maximum binding, declined progressively from 3 to 24 months.	Spiperone	52-61	dopamine receptor D2	Mus musculus	23-35
3838340-2	1985	Spiperone inhibition of [3H]5-HT binding in cortex was consistent with displacement from two sites with dissociation constants (KD) of 24 nM (5-HT-1A site) and 19 microM (5-HT-1B site) for spiperone.	Spiperone	0-9	5-hydroxytryptamine receptor 1A	Rattus norvegicus	142-149
3838340-2	1985	Spiperone inhibition of [3H]5-HT binding in cortex was consistent with displacement from two sites with dissociation constants (KD) of 24 nM (5-HT-1A site) and 19 microM (5-HT-1B site) for spiperone.	Spiperone	0-9	5-hydroxytryptamine receptor 1B	Rattus norvegicus	171-178
3838340-2	1985	Spiperone inhibition of [3H]5-HT binding in cortex was consistent with displacement from two sites with dissociation constants (KD) of 24 nM (5-HT-1A site) and 19 microM (5-HT-1B site) for spiperone.	Spiperone	189-198	5-hydroxytryptamine receptor 1B	Rattus norvegicus	171-178
3838340-5	1985	In the presence of 1 microM spiperone, a concentration that saturates the 5-HT-1A sites while having a minimal effect on 5-HT-1B sites, BrAcTFMPP displaced [3H]5-HT from a single site with a KD for BrAcTFMPP of 145 nM.	Spiperone	28-37	5-hydroxytryptamine receptor 1A	Rattus norvegicus	74-81
3838340-7	1985	In corpus striatum, 5-HT-1A sites, as defined with spiperone, represented 15% of the specific [3H]5-HT binding and 30 nM BrAcTFMPP also blocked about 15% of the binding.	Spiperone	51-60	5-hydroxytryptamine receptor 1A	Rattus norvegicus	20-27
4062976-0	1985	Dopamine D2 receptor dissociation constant for spiperone: identical values using 3H-labeled agonist or 3H-labeled antagonist.	Spiperone	47-56	dopamine receptor D2	Homo sapiens	0-20
6736961-1	1984	[3H]Spiperone specific binding by microsomal membranes isolated from sheep caudate nucleus is decreased by trypsin and phospholipase A2 (Vipera russeli), but is insensitive to neuraminidase.	Spiperone	4-13	phospholipase A2	Ovis aries	119-135
6241568-6	1984	In contrast, both behaviours in the reserpinised rat were inhibited stereospecifically by pindolol and by spiperone, which interact with 5-HT1 and 5-HT1A recognition sites.	Spiperone	106-115	5-hydroxytryptamine receptor 1A	Rattus norvegicus	147-153
3918224-4	1985	On the other hand, neither [3H]ligand binding was sensitive to phospholipases C and D. In contrast, prior treatment with phospholipase A2 (unheated) drastically decreased the [3H]5-HT binding and also affected the [3H]spiperone binding to some extent.	Spiperone	218-227	phospholipase A2 group IB	Rattus norvegicus	121-137
6488044-3	1984	We found that the S-2 binding sites (labeled by [3H]spiperone and displaced by ketanserin) consisted of two subtypes (S-2A and S-2B) which are discriminated by competition with methysergide.	Spiperone	48-61	ribosomal protein S2	Homo sapiens	18-21
6736961-6	1984	However, the presence of 2.5% albumin during phospholipase A2 action (1.5 micrograms/mg protein) prevents the inhibitory effect of phospholipase on [3H]spiperone binding to the membranes, although 28% of the total membrane phospholipid is hydrolysed.	Spiperone	152-161	phospholipase A2	Ovis aries	45-61
6136009-1	1983	The effect of beta-adrenoceptor agonists and antagonists on the binding of [3H]-spiperone in the frontal cortex of the rat has been examined to determine their possible interaction with the 5-hydroxytryptamine2 (5-HT2) receptor.	Spiperone	75-89	5-hydroxytryptamine receptor 2A	Rattus norvegicus	212-217
6330621-3	1984	Incubations of horizontal sections through the hippocampus with [3H]spiperone (1 nM) resulted in dense labeling restricted to the pyramid cell layer in CA1, the parasubiculum and layers I and II of the entorhinal area (EA), while the other hippocampal subfields contained moderate to low binding.	Spiperone	68-77	carbonic anhydrase 1	Rattus norvegicus	152-155
6325134-6	1984	Spiroperidol reverses the effects of CB 154 on POMC synthesis and POMC mRNA content; by itself, spiroperidol increases the IL synthesis of POMC, the IL content of POMC mRNA, and the capacity of the IL to synthesize immunoreactive alpha MSH.	Spiperone	0-12	proopiomelanocortin	Rattus norvegicus	47-51
6325134-6	1984	Spiroperidol reverses the effects of CB 154 on POMC synthesis and POMC mRNA content; by itself, spiroperidol increases the IL synthesis of POMC, the IL content of POMC mRNA, and the capacity of the IL to synthesize immunoreactive alpha MSH.	Spiperone	0-12	proopiomelanocortin	Rattus norvegicus	66-70
6325134-6	1984	Spiroperidol reverses the effects of CB 154 on POMC synthesis and POMC mRNA content; by itself, spiroperidol increases the IL synthesis of POMC, the IL content of POMC mRNA, and the capacity of the IL to synthesize immunoreactive alpha MSH.	Spiperone	0-12	proopiomelanocortin	Rattus norvegicus	66-70
6325134-6	1984	Spiroperidol reverses the effects of CB 154 on POMC synthesis and POMC mRNA content; by itself, spiroperidol increases the IL synthesis of POMC, the IL content of POMC mRNA, and the capacity of the IL to synthesize immunoreactive alpha MSH.	Spiperone	0-12	proopiomelanocortin	Rattus norvegicus	66-70
6325134-6	1984	Spiroperidol reverses the effects of CB 154 on POMC synthesis and POMC mRNA content; by itself, spiroperidol increases the IL synthesis of POMC, the IL content of POMC mRNA, and the capacity of the IL to synthesize immunoreactive alpha MSH.	Spiperone	96-108	proopiomelanocortin	Rattus norvegicus	47-51
6418525-7	1984	The effect of alpha MSH on LH release was blocked by pretreatment of the animals with alpha-methyl-paratyrosine, an inhibitor of catecholamine synthesis, as well as by pretreatment with an iv injection of spiroperidol, a dopamine receptor blocker.	Spiperone	205-217	proopiomelanocortin	Rattus norvegicus	14-23
6537998-2	1984	The binding of [3H]-spiperone to partially purified rat anterior pituitary plasma membranes was quantified throughout the estrous cycle in relation with the serum prolactin (PRL) levels.	Spiperone	20-29	prolactin	Rattus norvegicus	163-172
6621255-1	1983	Spiroperidol was covalently conjugated to bovine serum albumin (BSA).	Spiperone	0-12	albumin	Oryctolagus cuniculus	49-62
6417273-10	1983	Displacement experiments showed that specific [3H]TRH binding was displaced in the nanomolar range by spiperone and in the micromolar range by dopamine, whereas L-(--)-sulpiride was virtually inactive in displacing [3H]TRH.	Spiperone	102-111	thyrotropin releasing hormone	Bos taurus	50-53
6136427-5	1983	Parenteral administration of antipsychotic agents known to block catecholamine receptors, such as spiroperidol, alpha-flupenthixol, and (+)-butaclamol, reversibly antagonized enkephalin-induced depressions of neuronal activity.	Spiperone	98-110	proenkephalin	Rattus norvegicus	175-185
6418875-3	1983	TRH (2 or 20 mg/kg) significantly reduced specific [3H]spiperone binding to striatal membranes in 7- and 70-day-old rats compared to control, when the binding was examined in the membranes obtained from animals sacrificed 15 min and 150 min following TRH injection.	Spiperone	55-64	thyrotropin releasing hormone	Rattus norvegicus	0-3
6297690-5	1983	Spiroperidol significantly increased plasma Prl in both groups of animals, but the magnitude of the increase in Prl levels of MSG-treated rats was roughly one-third (p less than 0.005) that of control animals.	Spiperone	0-12	prolactin	Rattus norvegicus	44-47
6141122-7	1983	Since [3H]apomorphine and [3H]spiroperidol predominantly label pre- and post-synaptic dopamine receptors, it is concluded that MIF and its active analogs interact with presynaptic dopamine receptors.	Spiperone	30-42	macrophage migration inhibitory factor	Rattus norvegicus	127-130
7198992-4	1981	But the administration of d-Amp continuously over briefer periods induced large and phasic alterations in both d-Amp induced stereotypes and in spiroperidol accumulation.	Spiperone	144-156	transmembrane serine protease 5	Rattus norvegicus	28-31
7139336-0	1982	Ovine prolactin administration modifies [3H]spiperone binding to striatal membranes of rabbits.	Spiperone	44-53	prolactin	Oryctolagus cuniculus	6-15
6126526-6	1982	[3H]Spiperone binds to high-affinity sites in homogenates of nucleus accumbens, which are likely to be D-2 receptors.	Spiperone	4-13	solute carrier family 3 member 1	Rattus norvegicus	103-106
7075543-0	1982	[3H]spiroperidol identifies a D-2 dopamine receptor inhibiting adenylate cyclase activity in the intermediate lobe of the rat pituitary gland.	Spiperone	4-16	dopamine receptor D2	Rattus norvegicus	30-51
6126376-0	1982	[3H]N-propylapomorphine and [3H]spiperone binding in brain indicate two states of the D2-dopamine receptor.	Spiperone	28-41	dopamine receptor D2	Bos taurus	86-106
6286079-0	1982	Central injections of spiperone and GABA: attenuation of angiotensin II stimulated thirst.	Spiperone	22-31	angiotensinogen	Rattus norvegicus	57-71
6286079-1	1982	This study investigated the effects of injecting spiperone or gamma-aminobutyric acid (GABA) into the brain on drinking induced by angiotensin II injected into a lateral cerebral ventricle of the rat.	Spiperone	49-58	angiotensinogen	Rattus norvegicus	131-145
7198992-5	1981	Rats given continuous d-Amp for 24 h, allowed a 24 h drug-free period, and then injected evidenced a large potentiation of both stereotypies and in vivo accumulation of spiroperidol in the caudate nucleus, whereas after 5 days of continuous d-Amp administration rats showed attenuated stereotypies and decreased [3H]spiroperidol accumulation in the caudate, accumbens, and substantia nigra.	Spiperone	169-181	transmembrane serine protease 5	Rattus norvegicus	24-27
288372-2	1979	In rats, all functional dopamine antagonists (reserpine alone or combined with alpha-methyl-p-tyrosine or benserazide, haloperidol, spiroperidol, sulpiride) increased serum PRL levels.	Spiperone	132-144	prolactin	Rattus norvegicus	173-176
6102598-2	1980	Parenteral administration of antipsychotic agents known to block catecholamines receptors, such as spiroperidol, alpha-flupenthixol and (+)-butaclamol, reversibly antagonized enkephalin-induced depressions.	Spiperone	99-111	proenkephalin	Rattus norvegicus	175-185
6243670-0	1980	[3H]Spiperone binding to human anterior pituitaries and pituitary adenomas secreting prolactin, growth hormone, and adrenocorticotropic hormone.	Spiperone	4-13	growth hormone 1	Homo sapiens	96-110
6243670-0	1980	[3H]Spiperone binding to human anterior pituitaries and pituitary adenomas secreting prolactin, growth hormone, and adrenocorticotropic hormone.	Spiperone	4-13	proopiomelanocortin	Homo sapiens	116-143
6445044-7	1980	The prolactin-inhibiting effect of methysergide could be prevented by pretreatment of the lesioned rats with spiroperidol.	Spiperone	109-121	prolactin	Rattus norvegicus	4-13
510391-2	1979	Spiroperidol injected into the nucleus accumbens resulted in dose dependent decreases in lap volume and tongue extension.	Spiperone	0-12	leucine aminopeptidase 3	Rattus norvegicus	89-92
6460944-9	1982	Ketamine only weakly affected either [3H]5-HT or [3H]spiroperidol binding to 5-HT1 and 5-HT2 receptors respectively even at concentrations as high as 1 mM.	Spiperone	53-65	5-hydroxytryptamine receptor 5A	Homo sapiens	77-88
288372-6	1979	This was suggested by the inhibitory effect of pretreatment with the dopamine antagonist spiroperidol or with sulpiride on the prolactin-lowering effect of lisuride.	Spiperone	89-101	prolactin	Homo sapiens	127-136
187962-3	1976	Low doses of butyrophenones (haloperidol and spiroperidol) inhibited the rise in cyclic GMP levels and the stereotyped behaviour induced by amphetamine, but were without effect on the same biochemical and behavioural changes elicited by apomorphine.	Spiperone	45-57	5'-nucleotidase, cytosolic II	Mus musculus	88-91
6932044-3	1980	GTP decreases the potencies of dopamine agonists and of pergolide, but not of bromocriptine, to displace [3H]spiroperidol ([3H]Spi) from striatal membrane sites.	Spiperone	109-121	chromogranin A	Homo sapiens	127-130
887505-3	1977	Spiroperidol abolished potentializing effect of bradykinin on the central action of nialamide with L-DOPA and of noradrenaline.	Spiperone	0-12	kininogen 1	Homo sapiens	48-58
887505-4	1977	In animals receiving spiroperidol with bradykinin psychostimulatory action of noradrenaline was also not observed.	Spiperone	21-33	kininogen 1	Homo sapiens	39-49
33353947-3	2020	Here we describe the structure of human D2R in complex with spiperone (D2Rspi).	Spiperone	60-69	dopamine receptor D2	Homo sapiens	40-43
33353947-5	2020	Moreover, D2Rspi exhibited an extended binding pocket to accommodate spiperone"s phenyl ring, which probably contributes to the selectivity of spiperone to D2R and 5-HT2AR.	Spiperone	69-78	dopamine receptor D2	Homo sapiens	10-13
33353947-5	2020	Moreover, D2Rspi exhibited an extended binding pocket to accommodate spiperone"s phenyl ring, which probably contributes to the selectivity of spiperone to D2R and 5-HT2AR.	Spiperone	143-152	dopamine receptor D2	Homo sapiens	10-13
32328949-4	2020	Regeneration of the damaged microvascular bed under the action of spiperone resulted from recruiting of Notch1+ endothelial progenitor cells (CD45-CD31+CD34+) into the lungs and blockade of the inhibitory effect of dopamine on phosphorylation of VEGF-2 receptors in endothelial cells of different maturity.	Spiperone	66-75	notch 1	Mus musculus	104-110
33353947-0	2020	Structure of the dopamine D2 receptor in complex with the antipsychotic drug spiperone.	Spiperone	77-86	dopamine receptor D2	Homo sapiens	17-37
33194631-7	2020	Both penfluridol and spiperone induced AMPK activation and autophagy.	Spiperone	21-30	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	39-43
32328949-4	2020	Regeneration of the damaged microvascular bed under the action of spiperone resulted from recruiting of Notch1+ endothelial progenitor cells (CD45-CD31+CD34+) into the lungs and blockade of the inhibitory effect of dopamine on phosphorylation of VEGF-2 receptors in endothelial cells of different maturity.	Spiperone	66-75	protein tyrosine phosphatase, receptor type, C	Mus musculus	142-146
32328949-4	2020	Regeneration of the damaged microvascular bed under the action of spiperone resulted from recruiting of Notch1+ endothelial progenitor cells (CD45-CD31+CD34+) into the lungs and blockade of the inhibitory effect of dopamine on phosphorylation of VEGF-2 receptors in endothelial cells of different maturity.	Spiperone	66-75	platelet/endothelial cell adhesion molecule 1	Mus musculus	147-151
32328949-4	2020	Regeneration of the damaged microvascular bed under the action of spiperone resulted from recruiting of Notch1+ endothelial progenitor cells (CD45-CD31+CD34+) into the lungs and blockade of the inhibitory effect of dopamine on phosphorylation of VEGF-2 receptors in endothelial cells of different maturity.	Spiperone	66-75	CD34 antigen	Mus musculus	152-156
30808590-0	2019	Biotinylated-spiperone ligands for quantum dot labeling of the dopamine D2 receptor in live cell cultures.	Spiperone	13-22	dopamine receptor D2	Homo sapiens	63-83
30808590-1	2019	We have synthesized 3 analogs of the dopamine D2 receptor (D2 DR) antagonist spiperone that can be conjugated to streptavidin-coated quantum dots via a pegylated biotin derivative.	Spiperone	77-86	dopamine receptor D2	Homo sapiens	37-57
30808590-1	2019	We have synthesized 3 analogs of the dopamine D2 receptor (D2 DR) antagonist spiperone that can be conjugated to streptavidin-coated quantum dots via a pegylated biotin derivative.	Spiperone	77-86	dopamine receptor D2	Homo sapiens	59-64
25025465-8	2014	Treatment with spiperone, a small molecule identified using the Connectivity map database to correlate gene expression changes in response to drug treatment with those associated with PAFR stimulation, also induced silencing.	Spiperone	15-24	platelet activating factor receptor	Homo sapiens	184-188
30347827-16	2018	Docking studies showed that S14506, buspirone and spiperone bind in similar ways in the 5-HT1A receptor model and interacted with similar 5-HT1A receptor residues.	Spiperone	50-59	5-hydroxytryptamine receptor 1A	Homo sapiens	88-103
30347827-16	2018	Docking studies showed that S14506, buspirone and spiperone bind in similar ways in the 5-HT1A receptor model and interacted with similar 5-HT1A receptor residues.	Spiperone	50-59	5-hydroxytryptamine receptor 1A	Homo sapiens	138-153
25371112-4	2015	Here, we report the modeled structure of DRD4 alone and in complex with dopamine and spiperone, its natural agonist and antagonist, respectively.	Spiperone	85-94	dopamine receptor D4	Homo sapiens	41-45
25927611-4	2015	Spiperone is a selective D2 dopamine receptor antagonist.	Spiperone	0-9	dopamine receptor D2	Mus musculus	25-45
24914776-5	2014	We found that neuronal death induced by H2O2 exposure was inhibited by pretreatment with cabergoline, while this protective effect was eliminated in the presence of a dopamine D2 receptor inhibitor, spiperone.	Spiperone	199-208	dopamine receptor D2	Homo sapiens	167-187
24913578-3	2014	Apart from anti-inflammatory effect, spiperone suppressed bone marrow hemopoietic cells (CD3, CD45R (B220), Ly6C, Ly6G (Gr1), CD11b (Mac1), TER-119)-, Sca-1+, c-Kit+, CD34- and progenitor hemopoietic cells (granulocyte-erythroid-macrophage-megakaryocytic and granulocyte CFU).	Spiperone	37-46	CD3 antigen, epsilon polypeptide	Mus musculus	89-92
24913578-3	2014	Apart from anti-inflammatory effect, spiperone suppressed bone marrow hemopoietic cells (CD3, CD45R (B220), Ly6C, Ly6G (Gr1), CD11b (Mac1), TER-119)-, Sca-1+, c-Kit+, CD34- and progenitor hemopoietic cells (granulocyte-erythroid-macrophage-megakaryocytic and granulocyte CFU).	Spiperone	37-46	protein tyrosine phosphatase, receptor type, C	Mus musculus	94-99
24913578-3	2014	Apart from anti-inflammatory effect, spiperone suppressed bone marrow hemopoietic cells (CD3, CD45R (B220), Ly6C, Ly6G (Gr1), CD11b (Mac1), TER-119)-, Sca-1+, c-Kit+, CD34- and progenitor hemopoietic cells (granulocyte-erythroid-macrophage-megakaryocytic and granulocyte CFU).	Spiperone	37-46	lymphocyte antigen 6 complex, locus C1	Mus musculus	108-112
24913578-3	2014	Apart from anti-inflammatory effect, spiperone suppressed bone marrow hemopoietic cells (CD3, CD45R (B220), Ly6C, Ly6G (Gr1), CD11b (Mac1), TER-119)-, Sca-1+, c-Kit+, CD34- and progenitor hemopoietic cells (granulocyte-erythroid-macrophage-megakaryocytic and granulocyte CFU).	Spiperone	37-46	lymphocyte antigen 6 complex, locus G	Mus musculus	114-118
24913578-3	2014	Apart from anti-inflammatory effect, spiperone suppressed bone marrow hemopoietic cells (CD3, CD45R (B220), Ly6C, Ly6G (Gr1), CD11b (Mac1), TER-119)-, Sca-1+, c-Kit+, CD34- and progenitor hemopoietic cells (granulocyte-erythroid-macrophage-megakaryocytic and granulocyte CFU).	Spiperone	37-46	integrin alpha M	Mus musculus	126-131
24913578-3	2014	Apart from anti-inflammatory effect, spiperone suppressed bone marrow hemopoietic cells (CD3, CD45R (B220), Ly6C, Ly6G (Gr1), CD11b (Mac1), TER-119)-, Sca-1+, c-Kit+, CD34- and progenitor hemopoietic cells (granulocyte-erythroid-macrophage-megakaryocytic and granulocyte CFU).	Spiperone	37-46	integrin alpha M	Mus musculus	133-137
24913578-3	2014	Apart from anti-inflammatory effect, spiperone suppressed bone marrow hemopoietic cells (CD3, CD45R (B220), Ly6C, Ly6G (Gr1), CD11b (Mac1), TER-119)-, Sca-1+, c-Kit+, CD34- and progenitor hemopoietic cells (granulocyte-erythroid-macrophage-megakaryocytic and granulocyte CFU).	Spiperone	37-46	lymphocyte antigen 76	Mus musculus	140-147
24913578-3	2014	Apart from anti-inflammatory effect, spiperone suppressed bone marrow hemopoietic cells (CD3, CD45R (B220), Ly6C, Ly6G (Gr1), CD11b (Mac1), TER-119)-, Sca-1+, c-Kit+, CD34- and progenitor hemopoietic cells (granulocyte-erythroid-macrophage-megakaryocytic and granulocyte CFU).	Spiperone	37-46	lymphocyte antigen 6 complex, locus A	Mus musculus	151-157
24913578-3	2014	Apart from anti-inflammatory effect, spiperone suppressed bone marrow hemopoietic cells (CD3, CD45R (B220), Ly6C, Ly6G (Gr1), CD11b (Mac1), TER-119)-, Sca-1+, c-Kit+, CD34- and progenitor hemopoietic cells (granulocyte-erythroid-macrophage-megakaryocytic and granulocyte CFU).	Spiperone	37-46	CD34 antigen	Mus musculus	167-171